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Abstract 
I 
Recent reports suggest that candidemia caused by antifungal resistant strains 
is increasing in certain women and neonates populations. We evaluated the annual 
incidence of neonatal candidemia and the frequency of disease caused by different 
species of Candida among neonates in NICU (Neonatal intensive care unit) and 
gynecology OPD, J.N.M.C and FSHRC, Aligarh. 
The present study was conducted for a period of 1 year and 4 months from 
Nov. 2005 to March 2007 on samples isolated from Jawaharlal Nehru Medical 
College (JNMC) and Hospital, AMU and Feroz Specialist Hospital & Research 
Center (FSHRC), Aligarh. A total of 1470 vaginal yeast cultures were collected 
from pregnant ladies in the labor room and from Gynecology OPD of JNMC and 
FSHRC. Out of 1470 samples 600 samples were showing signs and symptoms of the 
disease. Of these 600 samples, only 175 samples were positive for Candida. From 
these 175 positive samples 200 Candida isolates were obtained. 
A total of 1825 samples were collected from NICU, JNMC, AMU Aligarh. 
Out of 1825 samples 500 samples were showing signs and symptoms of the disease. 
Out of these 500 samples only 138 samples were positive for Candida. From these 
138 positive samples 150 Candida isolates were obtained. These isolates were 
subjected to undergo morphological and biochemical identification and 
characterization was fiirther done. Clinical data such as age, sex, site of infection 
predisposing factors, and history of exposure to antiftingal and clinical out come of 
the patients are noted and shown in tables. 
Morphological test done by Lacto phenol Cotton Blue (LPCB), KOH 
Preparation, Gram Staining, Com Meal Agar (CMA), Germ Tube Test (GTT) and 
CHROM Candida Agar. Carbohydrate fermentation and carbohydrate assimilation 
test were used for biochemical characterization of the isolates. Antifungal 
susceptibility testing by Disc Diffusion method. 
In women C. albicans was 64.5%, C. glabrata 19%, C. parapsilosis 7%, C. 
tropicalis 5%, C. krusie 3% and C. kyfer 1.5%. While in neonates, C. albicans 
Sl.eiVo, C. tropicalis 18%, C. parapsilosis 12.67%, C. glabrata 10%, C. krusie 4%, 
and C. guilliermondi 2.67%. In gynecology unit C. glabrata was 2"'' most common 
species While in neonates 2"** most species was C. tropicalis. Blood is the most 
prevalent site of infection in neonates while in women vagina was the most 
prevalent site of Candida infection. In women least antifungal resistance was 
observed in Amphotericin-B and Clotrimazole (5.70% and 10.67% respectively). 
In patients attending gynecology OPD it is observed that the C. albicans is 
the most common pathogenic fungi followed by C. glabrata. Hormone replacement 
therapy and use of antibiotics and contraceptive are major risk factors for Candida 
infections in women. VLBWC (very low birth weight) neonates or SGA (small for 
gestational age) are higher risk of Candida as compared to LGAC (large for 
gestational age) neonates. Preterms are having more Candida infection as compared 
to terms neonates due to their low immunity and often are having problems in 
gaining weight. 
Our study indicates that transmission of Candida from mother to neonates is 
not the major cause of Candida infection in neonates but non-perinatal nosocomial 
transmission of Candida species is the predominant mode of acquisition by neonates 
in NICU, at AMU. Mother may be colonized with multiple strains of Candida 
simultaneously, colonizirig Candida strains can cause invasive disease in neonates; 
and molecular biology based techniques are necessary to determine epidemiologic 
relatedness of maternal and infant Candida isolates and to facilitate mode of 
transmission. 
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Chapter- 7 
Introduction 
Fungi are eukaryotic organisms that reproduce both in sexual and asexual 
fusion. They have also been called molds, yeast and mushrooms (Nader-Djalal et al. 
1998; Odds 1988). In 1954 Candida was officially accepted as the genus name for 
Monilis albicans (Winner et al 1964). Candida is yeast and the most common cause 
of opportunistic mycoses world wide. As well as being a pathogen and a colonizer, it 
is found in the environment, particularly on leaves, flowers, water, and soil. While 
most of the Candida sp. is mitosporic, some have known teleomorphic state and 
produce sexual sporesycoses worldwide. (Bodey 1966). The most common 
organism implicated in fungal infections is the ubiquitous Candida, which is found 
in the human digestive tract, mouth, and genital region (Eggimann et al 2003). 
Under normal circumstances, levels oi Candida are controlled by beneficial bacteria. 
However, if the bacteria-fungus balance is upset, by the use of antibiotics for 
example, or if the immune system is compromised, an overgrowth of Candida can 
occur, resuhing in infection (Braunwald 2001). Candida is a genus of yeasts. 
Clinically, the most significant member of the genus is Candida albicans, which can 
cause numerous infections (called candidiasis or thrush) in humans and other 
animals, especially in immunocompromised patients. Various Candida species are 
members of gut flora in animals, including C. albicans (Ryan et al 2004). Grown in 
the laboratory, Candida appears as large, round, white or cream {albicans is from 
Latin meaning 'whitish') colonies on agar plates. (www.DoctorFungus.org). 
Last decade has seen the sustained medical importance of opportunistic 
infections due to different Candida species mainly due to the worldwide increase in 
the number of immunocompromised patients, who are highly susceptible to 
opportunistic infections (Enfert et al 2007). Meanwhile, the genome sequence of 
several Candida species has been completed, enabling the detailed investigation of 
some aspects of their biology with the aid of post-genomic approaches. The basic 
knowledge gained from these investigations of pathogenic Candida, and related 
yeasts, can translate into innovations in the development of novel antifungal 
therapies, original approaches for targeted immuno-interventions, or highly sensitive 
diagnosis of fungal infections (Enfert et al 2007). 
Fungal overgrowth is encouraged by certain pH levels and the availability of 
sugar (glucose) (McGinnis et al 1996; Buddington et al 1996; Howard et al 1995). 
Candida are also responsible for a number of life-threatening opportunistic 
infections in AIDS patients and other immuno-compromised people - including 
patients treated in intensive care units (ICUs), cancer patients receiving 
chemotherapy, and organ transplant patients (Enfert et al 2007). 
People with the right conditions for fungal infection, such as a high sugar 
diet, are at higher risk. Also, Candida infections can be spread to vulnerable people 
with depressed immune systems who are in the hospital, where the fungus is 
commonly found on the hands of caregivers and where indwelling catheters can 
allow an infection to take hold (McGinnis et al 1996). 
Pathogenicity and clinical significance 
Infections caused by Candida spp. are in general referred to as Candidiasis. 
The clinical spectrum of candidiasis is extremely diverse. Almost any organ or 
system in the body can be affected. Candidiasis may be superficial and local or 
deep-seated and disseminated. Disseminated infections arise from hematogenous 
spread from the primarily infected locus. (Bielsa et al 1987; Bodey et al 1992; 
Bodey 1966). The colonies of Candida spp. are cream colored to yellowish, grow 
rapidly and mature in 3 days. The texture of the colony may be pasty, smooth, 
glistening or dry, wrinkled and dull, depending on the species (Larone 1995). 
The microscopic features of Candida sp. also show species-related 
variations. All species produce blastoconidia singly or in small clusters. 
Blastoconidia may be round or elongate. Most species produce pseudohyphae which 
may be long, branched or curved. True hyphae and chlamydospores are produced by 
strains of some Candida sp. (Abi-Said 1997). 
Although they are the members of the same genus, the various species do 
have some degree of unique behavior with respect to their colony texture, 
microscopic morphology on Commeal Tween 80 Agar at 25°C (Dalmau method) 
and fermentation or assimilation profiles in biochemical tests (Larone 1995). 
Histopathologic features 
Candida sp. should be differentiated from other clinically encountered 
yeasts, such as Blastoschizomyces, Cryptococcus, Geotrichum, Malassezia. 
Rhodotorula, Saccharomyces, and Trichosporon. Morphology on Commeal Tween 
80 Agar, capsule production, urease activity, ability to grow in presence of 
cycloheximide, growth pattern in Sabouraud broth, and fermentation assimilation 
profiles help in differentiation of Candida from other yeasts. Well-developed 
pseudohyphae and one-celled blastoconidia characterize the common species of 
Candida. Candida differs from Cryptococcus by having well-developed 
pseudohyphae. The lack of arthroconidia is the major microscopic feature which 
differentiates Candida from Trichosporon and Geotrichum, the two genera that 
produce abundant arthroconidia (Larone 1995). 
Candida species and features 
The genus Candida includes around 154 species. Among these, six are most 
frequently found in human infections. Among these Candida albicans is the most 
abundant and significant species, Candida tropicalis, Candida glabrata, Candida 
parapsilosis, Candida krusei, and Candida lusitaniae are also isolated as causative 
agents of Candidiasis. Importantly, there has been a recent increase in infections due 
to non-albicans Candida sp., such as Candida glabrata and Candida ki-usei (Abi-
Said 1997; Aisner et al 1976; Ari« et al 1996). Patients receiving fluconazole 
prophylaxis are particularly at risk of developing infections due to fluconazole-
resistant Candida krusei and Candida glabrata strains (Barchiesi et al 1993). 
Nevertheless, the diversity of Candida sp. that are encountered in infections 
is expanding and the emergence of other species that were rarely in play in the past 
but now a days their infections are increasing (Baily et al 1997; Blinkhorn et al 1989 
; Bonomo et al 1996; Borg-von Zepelin et al 1993). 
Table. 1 Species commonly causing invasive Candidiasis 
Species 
Candida albicans 
Candida tropicalis 
Candida glabrata 
Candida parapsilosis 
Candida krusei 
Candida lusitaniae 
Frequency 
50% 
15-30% 
15-30% 
15-30% 
- 1 % 
- 1 % 
Candida albicans 
Candida albicans is a diploid asexual fungus (a form of yeast), and a causal 
agent of opportunistic oral and vaginal infections in humans (Ryan et al 2004; Enfert 
et al 2007). Systemic fungal infections (fungemias) have emerged as important 
causes of morbidity and mortality in immunocompromised patients {e.g., AIDS, 
cancer chemotherapy, organ or bone marrow transplantation). In addition, hospital-
related infections in patients not previously considered at risk (e.g. patients on an 
intensive care unit) have become a cause of major health concern. 
C. albicans is among the gut flora, the many organisms that live in the 
human mouth and gastrointestinal tract. Under normal circumstances, C. albican.^ 
lives in 80% of the human population with no harmful effects, although overgrowth 
results in candidiasis. Candidiasis is often observed in immunocompromised 
individuals such as HIV-positive patients. Candidiasis also may occur in the blood 
and in the genital tract. Candidiasis, also known as "thrush", is a common condition 
that is usually easily cured in people who are not immunocompromised. To infect 
host tissue, the usual unicellular yeast-like form of Candida albicans reacts to 
environment and switches into an invasive, multicellular filamentous form (Ryan et 
al 2004). 
This species is the most commonly-isolated yeast in human disease. It has 
been implicated in both superficial and systemic disease. Recent reports of 
infections include corneal (Ritterband et al 2006), nail (Lange et al 2006), ear 
(Martin et al 2005), endocarditis (Levy et al 2006) and bloodstream (Viviani et al 
2006). Risk factors for infections with C. albicans include age of 65 years or abo\ e. 
immuno-suppression prior to steroid use, leukocytosis, intensive care unit stays, or 
presence of intravascular or urinary catheters. For those patients who have 
undergone cancer chemotherapy and who often appear less critically ill, infections 
are most likely to be caused by Candida species other than C. albicans (Cheng et al 
2005). Although this species continues to be the most common species isolated in 
bloodstream infections, reports show that the incidence is decreasing and the 
resistance is rare in neonatal populations (Fridkin et al 2006). Candida albicans is 
also a predominate species in fungal biofilms on medical devises (He et al 2006: 
Adler et al 2006). 
Genome 
One of the most interesting features of the C. albicans genome is the 
occurrence of numeric and structural chromosomal rearrangements as means of 
generating genetic diversity, named chromosome length polymorphisms 
(contraction/expansion of repeats), reciprocal translocations, chromosome deletions 
and trisomy of individual chromosomes. These karyotypic alterations lead to 
changes in the phenotype, which is an adaptation strategy of this fungus. These 
mechanisms will be better understood with the complete analysis of the C. albicans 
genome. 
The Candida albicans genome for strain SC5314 was sequenced at the 
Stanford DNA Sequencing and Technology Center (Jones et al 2004; Braun 2005). 
The genome of the WOl strain was sequenced by the Broad Institute of MIT and 
Harvard (Candida albicans at NCBI Taxonomy browser 2006 ). The sequencing of 
the C. albicans genome and subsequently of the genomes of several other medically 
relevant Candida species has profoundly and irreversibly changed the way Candida 
species are now investigated and understood (Enfert et al 2007). The C. albicans 
genome sequencing effort was launched in October 1996. Successive releases of the 
sequencing data and genome assemblies have marked the last 10 years, culminating 
with the release of the diploid assembly 19 that provided a haploid version of the 
genome along with data on allelic regions in the genome (Enfert et al 2007). A 
refined assembly 20 with the eight assembled C. albicans chromosomes has been 
released in the summer of 2006. Importantly, the availability of sequencing data 
prior to the completion of the genome sequence has made it possible to start C. 
albicans post-genomics early on. In this regard, genome databases have been made 
available to the research community providing different forms of genome 
annotation. These have been merged in a community-based annotation hosted by the 
Candida Genome Database 
The availability of the genome sequence has paved the way for the 
implementation of post-genomic approaches to the study of C. albicans: 
macroarrays and then microarrays have been developed and used to study the ('. 
albicans transcriptome; proteomics has also been developed and complements 
transcriptional analyses; furthermore, systematic approaches are becoming available 
to study the contribution of each C albicans gene in different contexts. Other 
Candida genome sequences have been, or are being, determined: C. glabrata, C. 
dubliniensis, C. parapsilosis, C. guilliennondii, C. lusitaniae, and C. tropicalis. 
These species will soon enter the post-genomic era as well and provide interesting 
comparative data. The genome sequences obtained for the different Candida species 
along with those of non-pathogenic hemiascomycetes provide a wealth of 
knowledge on the evolutionary processes that have shaped the hemiascomycete 
group as well as those that may have contributed to the success of different Candida 
species as pathogens (Enfert et al 2007) 
The genome of C. albicans is highly dynamic and this variability has been 
used advantageously for molecular epidemiological studies of C. albicans and 
population studies in this species. A remarkable discovery that has arisen from the 
genome sequence is the presence of a parasexual cycle in C. albicans. This 
parasexual cycle is under, the control of mating-type loci and switching between 
white and opaque phenotypes. Investigating the role that the mating process plays in 
the dynamics of the C. albicans population or in other aspects of C albicans biology 
and pathogenicity will undoubtedly represent an important focus for future research 
(Enfert et al 2007). 
Dimorphism 
In a process that superficially resembles dimorphism, C. albicans undergoes 
a process called phenotypic switching, in which different cellular morphologies are 
generated spontaneously. One of the classically studied strains that undergoes 
phenotypic switching is WO-1, which consists of two phases - one that grows as 
smooth white colonies and one that is rod-like and grows as flat gray colonies. The 
other strain known to undergo switching is 3153 A; this strain produces at least seven 
different colony morphologies. In both the WO-1 and 3153A strains, the different 
phases convert spontaneously to the other(s) at a low frequency. The switching is 
reversible, and colony type can be inherited from one generation to another. While 
several genes that are expressed differently in different colony morphologies ha\'e 
been identified, some recent efforts have focused on what might be controlling these 
changes. Further, whether there is a potential molecular link between dimorphism 
and phenotypic switching is a tantalizing question. 
In the 3153A strain, a gene called S1R2 (for silent information regulator) has 
been found that seems to be important for phenotypic switching. SIR2 was 
originally found in Saccharomyces cerevisiae (brewer's yeast), where it is involved 
in chromosomal silencing — a form of transcriptional regulation in which regions of 
the genome are reversibly inactivated by changes in chromatin structure (chromatin 
is the complex of DNA and proteins that make chromosomes). In yeast, genes 
involved in the control of mating type are found in these silent regions, and SIR2 
represses their expression by maintaining a silent-competent chromatin structure in 
this region. The discovery of a C. albicans SIR2 that is implicated in phenotypic 
switching suggests that it too has silent regions controlled by SIR2, in which the 
phenotype-specific genes may perhaps reside. 
Another potential regulatory molecule is Efglp, a transcription factor found 
in the WO-1 strain that regulates dimorphism, and more recently has been suggested 
to help regulate phenotypic switching. Efglp is expressed only in the white and not 
in the gray cell-type, and overexpression of Efglp in the gray form causes a rapid 
conversion to the white form. 
So far there are few data that says that dimorphism and phenotypic switching 
use common molecular components. However, it is not inconceivable that 
phenotypic switching may occur in response to some change in the environment as 
well as being a spontaneous event. How SIR2 itself is regulated in Saccharomyces 
cerevisiae may yet provide clues as to the switching mechanisms of C. albicans. 
Macroscopic morphology 
Colonies on Sabouraud dextrose agar at 25°C are white to cream, soft, and 
smooth to wrinkled. This isolate grows at 42°C and on media containing 
cycloheximide. 
Microscopic morphology 
On commeal following 72 hours incubation at 25 °C, abundant branched 
pseudohyphae and true hyphae with blastoconidia are present. The blastoconidia are 
formed in grape-like clusters along the length of the hyphae. Terminal 
chlamydoconidia may be formed with extended incubation (Sutton et al 1998). 
Candida slabrata 
Candida glabratais known for its decreased susceptibility to azoles (Magill 
SS 2006) but good susceptibility patterns to candins (Ernst et al 2002; Olson et al 
2005). Despite the decreased susceptibility to azoles, fluconazole prophylaxis has 
not contributed to an increased incidence of bloodstream infection caused by C. 
glabrata (Lin et al 2005).This species do, however, contribute to mortality in 
approximately 21% of pediatric patients with bloodstream infections (Fridkin et al 
2006). Although this species may be recovered from virtually all infection sites, 
recent reports of infection include corneal (Al-Assiri et al 2006), endocarditis (Lye 
et al 2005) vaginitis (De Vos et al 2005) and oral (Redding 2004). 
Macroscopic morphology 
Colonies on Sabouraud dextrose agar at 25°C are white, smooth and 
glistening. This isolate grows at 42°C but fails to grow on media containing 
cycloheximide. 
Microscopic morphology 
On commeal following 72 hours incubation at 25°C, only blastoconidia are 
observed. Yeast cells are quite small measuring only 2.5-4.0 x 3.0-6.0 |im as 
compared to C. albicans which measures 3.5-6.0 x 4.0-8.0 ^m (Kurtzman et a! 
2000). 
Candida dubliniensis 
This isolate is germ tube positive which accounts for its historic miss-
identification as C. albicans. Initially thought to be associated only with HIV 
disease, several reports have been published since its description implicating it in 
non-HIV associated infection as well (Carr et al 2005; Faggi et al 2005; Miron et al 
2005). Molecular analysis show that C dubliniensis is distinct from C. albicans by 
13-15 nucleotides in the ribosomal RNA gene sequences (Sullivan et al 1995). Early 
reports purported that C. dubliniensis was responsible for fluconazole-resistant 
thrush but susceptibility studies reveal that it's categorical distribution is similar to 
C. albicans with isolates ranging from susceptible to resistant. 
Macroscopic morphology 
Colonies on Sabouraud dextrose agar at 25°C are white to cream, soft, and 
smooth to wrinkled. This isolate has poor to no growth at 42°C. Colonies grown on 
CHROMagar are dark green as opposed to the light blue-green exhibited by C. 
albicans. 
Microscopic morphology 
On commeal following 72 hours incubation at 25°C, abundant branched 
pseudohyphae and true hyphae with blastoconidia are present. Many strains produce 
an abundance of chlamydoconidia resulting in excess of 25-30. being observed in 
each microscopic field. Chlamydoconidial arrangement includes single, pairs, 
chains, and clusters. 
Candida euilliermondii 
Macroscopic morphology 
Candida guilliermondii colonies are flat, moist, smooth, and cream to yellow 
in color on Sabouraud dextrose agar. It does not grow on the surface when 
inoculated into Sabouraud broth (Larone 1995; Sutton et al 1998). 
Microscopic morphology 
On commeal tween 80 agar and at 25°C after 72 h, it produces clusters of small 
blastospores along the pseudohyphae and particularly at septal points. Pseudohyphae 
are short and few in number (Larone 1995; Sutton et al 1998). 
Candida kefvr 
This species has been reported as an emerging pathogen (Corpus et al 2004). 
This species may have been previously reported in the literature by the obsolete 
name of Candida pseudotropicalis. Reported infections include bum wounds (Gupta 
et al 2004) blood (Pfaller et al 2004), and vaginal (Erdem et al 2003). 
Macroscopic morphology 
Colonies on Sabouraud dextrose agar at 25°C are cream to brown, glossy, 
and smooth. This isolate has grows at 37°C and on media containing cycloheximide. 
Microscopic morphology 
On commeal following 72 hours incubation at 25°C, highly-branched 
pseudohyphae are found. This species is not distinguishable from several other 
species on CHROMagar Candida (Hospenthal et al 2006). 
Candida lusitaniae 
Candida lusitaniae is known for amphotericin B resistance. The first report 
of fatal infection occurred in a neutropenic patient where the initial isolate was 
susceptible to amphotericin B but subsequent isolates had developed amphotericin B 
resistance (Pappagianis et al 1979). It is well-documented that this species is able to 
develop resistance, but some strains display resistance prior to amphotericin B 
therapy (Merz 1984). Although amphotericin B resistance is a concern, reports exist 
where amphotericin B has been used to successfully treat fungemia in severely 
immunocompromised patients (Blinkhom et al 1989). 
Macroscopic morphology 
Colonies on Sabouraud dextrose agar at 25°C are white to cream, glistening, 
and smooth but may be rugose. Colonies may be fringed with pseudohyphae. This 
isolate grows both at 42°C and on media containing c>cloheximide. 
Microscopic morphology 
On commeal following 72 hours incubation at 25°C, abundant branched 
pseudohyphae may be present. Some strains have rudimentary to no pseudohyphae. 
Candida parapsilosis 
Macroscopic morphology 
Candida parapsilosis colonies are white, creamy, shiny, and smooth or 
wrinkled on Sabouraud dextrose agar. It does not grow on the surface when 
inoculated into Sabouraud broth (Larone 1995; Sutton 1998). 
Microscopic morphology 
On commeal tween 80 agar and at 25°C after 72 h, it produces blastospores 
which are located along the pseudohyphae. Typically, the pseudohyphae may be 
curved and large mycelial- (hyphal) elements which are called "giant cells" ma) be 
observed (Larone 1995; Sutton 1998). 
Candida tropicalis 
Macroscopic morphology 
On Sabouraud dextrose agar, Candida tropicalis colonies are cream-colored 
with a slightly mycelial border. It may produce a thin surface film and bubbles when 
grown in Sabouraud broth (Larone 1995; Sutton 1998). 
Microscopic morphology 
On commeal tween 80 agar and at 25°C after 72 h, it produces oval 
blastospores which are located along the long pseudohyphae. The blastospores may 
appear singly or in clusters. The pseudohyphae branch abundantly. Candida 
tropicalis may also produce true hyphae (Larone 1995; Sutton 1998). 
Other species of Candida 
Apart from the Candida sp. discussed separately in other pages, there are others less 
frequently involved in infections. Major characteristics of these other Candida sp. 
are summarized in the Table below. 
Table. 2 Microscopic and macroscopic features of different Candida spp. 
SPECIES MACROSCOPIC MORPHOLOGY* 
MACROSCOPIC 
MORPHOLOGY** 
SPECIAL 
NOTES REFERENCES 
Candida 
ciferrii 
White to cream in 
color, powdery 
Pseudohyphae, true 
hyphae, branching 
chains of 
blastospores 
Sutton etal 1998 
Candida 
famata 
White to cream in 
color, smooth 
Small blastospores, 
no pseudohyphae 
Barchiesi et al 1999; 
Carrillo-Munoz et al 
1999; Quindos etal 
1994 
Candida 
lambica 
White to cream in 
color, smooth 
Pseudohyphae, 
branching chains of 
elongate blastospores 
Sutton etal 1998 
Candida 
lipolytica 
White in color, 
dry, cerebriform 
or creamy 
Branching true 
hyphae, rare, short, 
and elongate 
branching 
blastospores 
Nosocomial 
bloodstream 
pathogen 
May form 
pellicles in 
Sabouraud broth 
Larone 1995; Shin et 
al 2000; Sutton et al 
1998 
Candida 
norvegensis 
White to 
yellowish, may 
have pinkish to 
beige color from 
reverse, has a 
specific odor 
Small blastospores, 
rare pseudohyphae 
May be resistant 
to fluconazole 
Ahearn et al 
Hood et al 
1984; 
996 
Candida 
rugosa 
White to cream in 
color, wrinkled 
Branching, short, 
pseudohyphae 
Nosocomial 
bloodstream 
pathogen 
May be resistant 
to nystatin 
Carrillo-Munoz, et al 
1999; Dib etal 1996; 
Dubeetal 1994; 
Sutton etal 1998 
Candida 
viswanathii 
No typical 
morphology 
defined 
No typical 
morphology defined 
Carrillo-Munoz, et al 
1999 Collier etal 
1998; Elie etal 
1998;Mannarelli et 
al 1998 
Candida 
zeylanoides 
White to cream in 
color, smooth, 
dull 
Pseudohyphae, 
blastospores forming 
feather-like 
appearance along the 
pseudohyphae 
Causative agent 
of fungemia, 
arthritis 
May form 
pellicles in 
Sabouraud broth 
Bisbeetal 1987; 
Larone 1995; Sutton 
etal 1998 
Colony colour on Sabroud Dextrose Agar; ** Colony colour on Cornmeal Agar 
Candida infections 
Candidiasis is mostly an endogenous infection, arising from overgrowth of 
the fungus inhabiting in the normal flora. However, it may occasionally be acquired 
from exogenous sources (such as catheters or prosthetic devices) (Band et al 1979) 
or by person-to-person transmission (such as oral candidiasis in neonates of mothers 
with vaginal candidiasis or endophthalmitis following corneal transplantation from 
an infected donor) (Behrens-Baumann et al 1991). 
Fungal infections have increased in medical and surgical intensive care units 
with associated mortality and morbidity (Beck-Saque et al 1993; Jarvis 1995). 
Intensive care patients are susceptible to fungal infections during their stay in the 
hospital. Candida albicans has become a major nosocomial pathogen in the 
hospitals. It is the fourth leading species found in positive blood cultures in U.S. 
hospitals (Benerjee 1991). The growing list of resistant pathogens, nosocomial 
transmission and lack of an effective antifungal drug with a lower toxicity, are the 
potential problems associated with systemic fungal diseases. Epidemiological 
studies have shown that Candida infections may be transmitted from patient to 
patient and from health care provider to patients (Bauer et al 1990). 
Candida species are the leading cause of nosocomial infections (Beck-Saque 
et al 1993; Jarvis 1995). Candidemia is frequently associated with the signs and 
symptoms (Rex et al 2000; Pappas et al 2004). A recent epidemiological study of 
sepsis revealed that the annual number of cases of sepsis caused by fungal organisms 
increased by 20.7% between 1979 and 2000 (Guyer et al 1995). This is likely due to 
an increased prevalence of susceptible hosts, who receive intensive care therapies, 
immunosuppressive therapies associated with transplantation, and broad-spectrum 
antibiotics (Fanaroff et al 1998; Makhoul et al 2001). 
Candidal infections are an emerging problem in hospital medical practice. 
Candida infections differ markedly between hospitalized children and hospitalized 
adults (Pappas et al 2003; Wey et al 1988; Rentz et al 1998; Gudlaugsson et al 
2003). Previously C. albicans was responsible for nearly 80% of candidemia in 
many hospitals. Recently shift has occurred in the distribution of infections has 
changed, non albicans Candida species are being increasingly detected (Pfalier et al 
1998a; Nguyen et al 1996; Martin et al 1992). 
The clinical prevalence of candidiasis has changed (Rippon 1988). Invasive 
fungal infections (IFI) are increasing by less common Candida species (Rattan 
1999; Chakrabarti et al 1999; Hadley et al 2002). 
1. Vaginal candidiasis (Vulvovaginal Candidiasis) 
Vaginitis is the most frequent gynecologic diagnosis encountered b} 
physicians who provide primary care to women (Kent 1991; McCue 1989; Carr et al 
1998; Sobel 1999b; Haefner 1999). Accurate diagnosis can be elusive; complicating 
treatment (Eschenbach et al 1989; Schaaf et al 1990; Sobel 1997; Berg et al 1984). 
Furthermore, the availability of over the counter medications increases the 
likelihood of inappropriate or partial treatment of vaginitis (Horowitz et al 1992). 
Epidemiology 
The prevalence and causes of vaginitis are uncertain, in part because the 
condition is so often self-diagnosed and self-treated. In addition, vaginitis is 
frequently asymptomatic or has more than one cause. Most experts believe that up to 
90 percent of vaginitis cases are secondary to bacterial vaginosis, vulvovaginal 
candidiasis and trichomoniasis (Sobel 1997; 1999b). Noninfectious causes include 
vaginal atrophy, allergies and chemical irritation. 
Vaginal candidiasis is primarily an infection of premonoposal woman. It 
suggests that gonadal hormones may play a major role in the pathogenesis of the 
infection (Reed 1992).In post menopausal woman vaginal carriage of Candida is 
expected to be much lower because of estrogen deficiency (Sobel 1997). 
Vulvovaginal candidiasis is the second most common cause of vaginitis in 
the United States and the most common cause in Europe (Kent 1991). An estimated 
75 percent of women have vulvovaginal candidiasis at some time in life, and 
approximately 5 percent of women have recurrent episodes (Monif 1985; Foxman 
1990; Sobel 1993; Geiger et al 1996). Candida albicans is the infecting agent in 80 
to 90 percent of patients (Sobel 1997; Horowitz 1992). Recently, the frequency of 
non-albicans species (e.g., Candida glabrata) has increased, possibly secondary to 
greater use of over-the-counter antifungal products (Horowitz 1992) 
Risk factors for uncomplicated vulvovaginal candidiasis have been difficult 
to determine (Sobel et al 1998a). Studies have shown that the risk of this infection is 
increased in women who use oral contraceptive pills, a diaphragm and spermicide, 
or an lUD (Barbone et al 1990; Spinillo et al 1995; Hooton et al 1994). Other risk 
factors include young age at first intercourse, intercourse more than four times per 
month and receptive oral sex. (Foxman 1990; Geiger et al 1996; Sobel et al 1998a; 
Skinner 1996; Eckert et al 1998) The risk of vulvovaginal candidiasis is also 
increased in some women who have diabetes, are pregnant or are taking antibiotics. 
(Foxman 1990; Sobel et al 1998a; Spinillo et al 1999) 
Complications of vulvovaginal candidiasis are rare. Chorio-amnionilis in 
pregnancy and vulvar vestibulitis syndrome have been reported (Cotch et al 1998: 
Pagano 1999). Establishing Candida species as the cause of vaginitis can be difficult 
because as many as 50 percent of asymptomatic women have candidal organisms as 
part of their endogenous vaginal flora (Sobel 1993). Candidal organisms are not 
transmitted sexually, and episodes of vulvovaginal candidiasis do not appear to be 
related to the number of sexual partners (Foxman 1990; Geiger et al 1996; Sobel et 
al 1998a). Treafing the male partner is unnecessary unless he is uncircumcised or has 
inflammafion of the glans of the penis (MMWR Morb Mortal Wkly Rep 1998). 
Candida vaginifis is a common problem attributable to over growth of 
Candida species; it is estimated that 75% of all women will experience an episode in 
their lifetime (Sobel 1997; 1999b). By the age of 25 years, nearly one-half of all 
college-age women will have at least 1 episode of Candida vaginitis (Geiger et al 
1995). Candida albicans accounts for 80%-95% of all episodes oi Candida vaginitis 
worldwide (Sobel 1997; 1999b). Like other topical Candida infections, Candida 
vaginitis is treated effectively with azole-based antifungal drugs. However, such 
therapy can be compHcated by the emergence of drug-resistant yeasts (Sobel 1998a. 
1998b; 1999a). Prolonged exposure to fluconazole can shift the predominant vaginal 
yeast flora from C. albicans to more intrinsically azole-resistant species, as has been 
described for immunosuppressed women (Sobel 1998b; Vazquez et al 1999). In the 
1990s, there was a significant increase in the prevalence of drug-resistant fungal 
infections due to Candida species in patients hospitalized for mucosal or systemic 
diseases (Nguyen et al 1996; Pfaller et al 1998b. 1999). The widespread application 
of fluconazole or related azole antifungals is postulated to promote selection of 
resistant subpopulations by shifting colonization to more naturally resistant species, 
such as Candida krusei or Candida glabrata (Alexander et al 1997; Pfaller 1995: 
Rex et al 1995a). Alternatively, azole-resistant subspecies have arisen in vivo and in 
vitro that show changes in the target enzyme lanosterol 14- a demethylase, in 
expression of multidrug efflux pumps, or in both (Marr et al 1998; Sanglard et al 
1995; 1998). Numerous effective topical vaginal antimycotic agents are available 
that provide high cure rates with favorable therapeutic indexes. Given the growing 
correlation between azole antifungal exposure and emergence of drug-resistant 
Candida species, there is a concern that this problem may be exacerbated in health) 
women by use of over-the-counter (OTC) products, which became available in the 
early to mid-1990s for self-treatment of vaginitis (Sobel 1998c; 1999a). Most 
notably, because many of the OTC drugs are azole based, it is likely that frequent or 
prolonged use of these products has the potential to select for widespread drug 
resistance. In fact, cross-resistance between OTC drugs (miconazole, clotrimazole, 
and tioconazole) and fluconazole has been observed in clinical isolates of C. 
glabrata and C. albicans (Arias et al 1996; Cross et al 2000).To better address this 
concern, a multicent. exposure to OTC azole antifungal drugs is not associated with 
widespread colonization of drug-resistant Candida species in the vaginal flora of 
largely healthy college-age women. In contrast to oropharyngeal candidiasis in 
patients with AIDS, azole resistance has only been reported in 1 case of vaginitis 
caused by C. albicans (Sobel et al 1996). In vitro resistance remains rare among 
isolates from women with vaginitis due to C. albicans, even among isolates from 
HIV-positive women, in whom there is a tendency for such infections to occur in the 
oral cavity. The same is true of patients with recurrent Milvovaginal candidiasis in 
which vaginal isolates remain susceptible to azole-based antifungal drugs and do not 
show increased resistance to any drug despite long-term exposure to azoles (Lynch 
et al 1996). The widespread use of azoles has led to an increase in the prevalence of 
fluconazole-resistant non-C albicans species, especially C. glabrata (Sobel 1998b: 
Vazquez et al 1999; Nguyen et al 1996; Cross et al 2000: Hitchcock et al 1993; Xu 
et al 1999). The presence of asymptomatic women colonized with azole resistant 
strains has important implications for therapeutic management of future vaginitis 
episodes in women. Perhaps of more concern is the possibility that a primary drug 
resistant colonizing strain could predominate at later time if the women become 
immunosuppressed. Furthermore, the spread of these primar\ drug-resistant 
colonizers by sexual transmission is a distinct possibility (Barchiesi et al 1995). 
If candidiasis is caused by the host's original commensal strain or strains. 
knowledge of the yeast microflora of high-risk patients before the manifestation of 
candidiasis (e.g., susceptibility to different antifungal drug.")) could lead to improved 
strategies for prophylaxis and treatment (Xu et al 1999). 
Another concern is the transmission of drug-resistant commensal colonizing 
strains to family members. MuUer (MuUer et al 1999) reported that transmission of 
azole-resistant strains from symptomatic HIV-infected patients with orophar)ngeal 
candidiasis to asymptomatic family members is possible and ma\ represent a 
previously underappreciated risk for families that include members infected with 
HIV. The acquisition of an azole-resistant strain of C. albicans b> an asymptomatic 
patient has important clinical implications, especially in high-risk populations where 
presentation of oropharyngeal candidiasis may result in therapy refractory to azoles. 
The selection of non-C. albicans species, especially C glabrata. in HIV-positive 
women receiving fluconazole therapy is well established, although C. albicans is 
still the predominant pathogen, at 185 percent of all isolates from HlV-seronegative 
women (Sobel 1999b). 
Symptoms and diagnosis of Vulvovaginal Candidiasis 
Women with vulvovaginal candidiasis frequently complain of pruritus, 
vaginal irritation and dysuria. Vulvovaginal itching generally is not a normal finding 
in healthy women; if this symptom is present, other dermatologic conditions (e.g.. 
lichen sclerosis and, rarely, vulvar cancer) should also be considered, especially in 
the absence of candidal infection (Haefner 1999; Reilly et al 1991). 
In vulvovaginal candidiasis, the discharge is usually white and thick, with no 
odor and a normal pH. Women with candidiasis can have vulvar and vaginal 
erythema and, occasionally, scaling and fissures of vulvar tissue (Sobel 1997: 
ACOG technical bulletin 1996). Microscopic examinations of wet-mount and KOH 
preparations are positive in 50 to 70 percent of patients with candidal infections 
(ACOG technical bulletin 1996). In patients with a negative microscopic 
examination but symptoms compatible with yeast vaginitis, a Gram stain or a culture 
using Nickerson's medium or Sabouraud's dextrose agar may be helpful (Haefner 
1999; Sobel 1998a). Other tests, such as the Pap smear or the latex agglutination 
test, provide no advantage over microscopic techniques (Monif 1985; Sobel 1993a: 
1998a). 
Causes of Recurrence 
Although Candida albicans is the pathogen identified in most patients with 
vulvovaginal candidiasis, other possible pathogens include Candida tropicalis and 
Candida glabrata. Increasingly, Candida species other than C albicans have been 
found to cause yeast vaginitis (i.e., 9.9 percent of cases in 1988 and 17.2 percent o'i 
cases in 1995) (Spinillo et al 1997a). In fact, recurrent infections may be caused b\ 
the resistance of non C. albicans species to antiftingal agents. 
In vitro studies have shown that imidazole antifungal agents such as 
miconazole and clotrimazole are not as effective against non C albicans fungi. C. 
tropicalis and C. glabrata are 10 times less sensitive to miconazole than is C. 
albicans (Horowitz 1991). Imidazoles are still the first-line treatment for C albicans 
infections. A 1993 in vitro study examined more than 250 strains of C. albicans and 
found that no strain was resistant to ketoconazole, itraconazole and clotrimazole 
(Fongetal 1993.) 
Noncompliance with a treatment regimen may result in persistent infection 
that is mislabeled as a recurrence. For example, a patient may not complete the 
entire course of antifungal therapy, especially if an inconvenient topical treatment 
has been prescribed. A recurrence may also represent an inadequately treated 
infection. Between 15 and 20 percent of women with negative cultures after 
treatment have positive cultures within three months (Horowitz et al 1992). If an 
infection recurs at least three months after the previous episode, it is more likely to 
be caused by a different C. albicans strain (O'Connor et al 1986). 
Antibiotics are often implicated as a cause of recurrent vulvovaginal 
candidiasis. Frequent antibiotic use decreases protecti\e vaginal flora and allows 
colonization by Candida species (Reed 1992). The risk of a yeast infection increases 
with the duration of antibiotic use, but no specific antibiotic has been shown to be 
more likely to cause yeast infections (Spinillo et al 1999). 
Diabetes mellitus is often considered a predisposing factor for recurrent 
vulvovaginal candidiasis. Hyperglycemia enhances the ability of C. albicans to bind 
to vaginal epithelial cells (Bohannon 1998). However, unless other symptoms are 
suggestive of diabetes, patients with recurrent vulvovaginal candidiasis are rarely 
found to be diabetic (Reed 1992). 
Contraceptive methods may also promote recurrences of vulvovaginal 
candidiasis. Use of spermicidal jellies and creams increases susceptibility to 
infection by altering the vaginal flora and increasing the adhesion of Candida 
organisms. Women who take oral contraceptive pills have a higher rate of 
vulvovaginal candidiasis (Sobel 1998a). According to one theory. Candida cells 
have estrogen and progesterone receptors that, when stimulated, increase fungal 
proliferation (Reed 1992). 
Women who are prone to recurrent vulvovaginal candidiasis may have 
deficient cell-mediated immunity. Similarly, persons with acquired 
immunodeficiency syndrome are susceptible to systemic candidal infection. Some 
studies suggest that 40 to 70 percent of women with recurrent vulvovaginal 
candidiasis have some specific anergy resulting in a subnormal T-lymphocyte 
response to Candida (Sobel 1992a). One study found that Lewis A and B blood 
group antigens on the vaginal epithelium are protective against candidal infection 
(Hilton etal 1995). 
Mechanical factors may also be important. Perspiration associated with 
tightly fitted clothes or poorly ventilated underwear increases local temperature and 
moisture. Mechanical irritation of the vulvovaginal area by clothing or with sexual 
intercourse may also predispose already colonized areas to infection. One study 
demonstrated a positive relationship between the monthly frequency of sexual 
intercourse and the incidence of recurrent vulvovaginal candidiasis (Spinillo et al 
1993). 
Dietary habits have been suggested as causes of recurrent vulvovaginal 
candidiasis. However, most studies do not support a role for dietary factors in the 
etiology of recurrences, and adherence to strict diets has not been beneficial (Reed 
1992). 
The role of sexual transmission is controversial. One study found identical 
Candida strains in the sexual partners of 48 percent of women with recurrent 
infections. (O'Connor et al 1986) A randomized, controlled trial evaluated the effect 
that treating male sexual partners with oral ketoconazole had on the recurrence rates 
for vulvovaginal candidiasis (Fong 1992 a). The recurrence rates in the treated and 
untreated partner groups were found to be similar at six months and one year. 
Topical antifungal therapy has been ineffective in male sexual partners, probably 
because of the presence of reservoirs not reached by this treatment. In summary, no 
clinical trial has found that the treatment of male sexual partners prevents 
recurrences of vulvovaginal candidiasis in women. 
Some investigators have advocated the elimination of Candida from the 
gastrointestinal tract. The rationale is that reinfection from an intestinal reservoir 
contributes to vaginal recurrences. However, studies have not found an association 
between recurrent vulvovaginal candidiasis and the presence of intestinal Candida 
(Horowitz et al 1992). 
Treatment 
If a patient has infrequent recurrences, the simplest and most cost-effective 
regimen involves self-diagnosis and the early initiation of topical therapy. A 
prospective randomized, open, crossover study in 23 women with proven recurrent 
vulvovaginal candidiasis examined the efficacy and cost benefit of monthly 
prophylaxis compared with empiric self-treatment at the onset of symptoms (Fong 
1994). Patients were randomized to receive one 500-mg dose of clotrimazole 
intravaginally each month with the menses for six months or one 500-mg dose of 
clotrimazole intravaginally at the onset of symptoms. After six months, patients 
were switched (crossover) to the other regimen. 
If a woman with an established diagnosis of recurrent vulvovaginal 
candidiasis does not respond to an imidazole, infection with a resistant non C 
albicans species may be present. Terconazole vaginal cream (Terazol) is the agent 
of choice when infection with a species other than C albicans is suspected. The 
potent interference of this agent with the cytochrome P450 isoenzymes makes C. 
tropicalis and C. glabrata more susceptible to treatment. 
After the acute episode of recurrent vulvovaginal candidiasis has been 
treated, subsequent prophylaxis or maintenance therapy is essential. In one clinical 
trial, women with a history of recurrent vulvovaginal candidiasis were randomized 
to receive 400 mg of ketoconazole for 14 days or clotrimazole in the form of 100-
mg vaginal suppositories for seven days (Sobel et al 1994). One week after 
treatment, the clinical cure rate was higher than 80 percent in both groups. Two 
months after treatment, in the absence of any maintenance therapy, 53 percent of 
women in the ketoconazole treatment group and 63 percent of those in the 
clotrimazole treatment group had recurrences. 
Several maintenance regimens have been studied. In one clinical trial, 74 
women with recurrent vulvovaginal candidiasis were treated for an acute episode 
with 400 mg of ketoconazole per day for 14 days (Sobel et al 1986). The women 
were then randomized to receive one of three treatments: placebo, 400 mg of 
ketoconazole administered orally for five days after the menses for six months, or 
100 mg of ketoconazole administered orally each day for six months. The six-month 
recurrence rates were 71 percent for the placebo group, 29 percent for the cyclic-
regimen group and 5 percent for the daily-regimen group. 
Maintenance therapy needs to be given frequently enough to prevent vaginal 
regrowth, but the optimal dosing interval is not clear. One study suggested that the 
weekly administration of 0.8 percent terconazole vaginal cream is nearly as 
effective as daily treatment with ketoconazole (Stein et al 1996). Similar efficac\ 
has been noted for twice-weekly intravaginal treatment with 200 mg of clotrimazole 
(Fong 1992 b). 
A monthly 150-mg dose of orally administered fluconazole has been shown 
to reduce the incidence of recurrences by 50 percent (Sobel 1992b). Itraconazole, in 
a dosage of 200 mg (Creatsas et al 1993) or 400 mg (Spinillo et al 1997b) 
administered orally once a month, also has been found to decrease the recurrence 
rate by approximately 50 percent. Boric acid, administered in a 600-mg vaginal 
suppository twice daily for two weeks and then daily during menstruation, has been 
effective in the treatment, of women with resistant infection (Jovanovic et al 991). 
However, the use of boric acid is limited by significant local irritation and the 
possibility of intoxication (Thai et al 1993). 
Based on the findings of Erika (Erika 2000), ketoconazole (Nizoral) 
administered orally once a day, clotrimazole (Gyne-Lotrimin) administered 
intravaginally twice weekly, terconazole administered intravaginal ly once a week, 
and fluconazole (Diflucan) or itraconazole (Sporanox) administered orally once a 
month have been relatively effective in reducing the recurrence rate for 
vulvovaginal candidiasis. 
Most studies recommend prophylaxis for six months. Then the woman is 
reevaluated. Many womeahave recurrences once prophylaxis is discontinued. Thus, 
they may need to stay on medication for a longer period. 
A 1992 crossover study assessed the association between the daily ingestion 
of yogurt containing Lactobacillus acidophilus and the prevention of recurrent 
vulvovaginal candidiasis (Hilton et al 1992). Women were assigned to a yogurt-free 
diet or a yogurt-containing diet. Although only 13 of 21 women completed the 
protocol, the women who ingested yogurt had a threefold reduction in infection. The 
authors of the study concluded that daily ingestion of 8 oz of yogurt containing L 
acidophilus decreased the rate of candidal infection. A second study showed no 
difference in infection rates between women who ingested pasteurized yogurt and 
women who ingested yogurt that contained L. acidophilus (Shalev et al 1996). 
Additional evidence is needed before management recommendations can be made. 
In addition to cost, other factors may determine the most appropriate 
regimen. Compliance rates are greater for medications that are taken orally rather 
than intravaginally. However, the potential for systemic toxicity and drug 
interactions is greater with orally administered medications. 
Gastrointestinal side effects occur in 15 percent of patients treated with 
orally administered antifungal agents (Fong 1996). In addition, hepatic toxicity has 
been noted in one of 15,000 persons treated with orally administered ketoconazole 
(Titusville 1997). Although clotrimazole therapy may cause local discomfort, it is 
less frequently associated with systemic toxicity (headache occurs in 9 percent of 
recipients and abdominal pain is a Compared with ketoconazole, fluconazole is less 
likely to be toxic. Because fluconazole is administered orally, treatment compliance 
is better than with clotrimazole, which is administered intravaginally. Patients 
treated with fluconazole report headache (12 percent), abdominal pain (7 percent) 
and nausea (4 percent) (Sobel et al 1995). 
Many antifungal agents have significant interactions with other medications. 
For example, interactions have been noted between fluconazole and warfarin 
(Coumadin), oral hypoglycemic agents, phenytoin (Dilantin), theophylline and 
rifampin (Rifadin) (Desai et al 1996). Other drugs reported to interact with 
fluconazole include cyclosporine (Sandimmune), zidovudine (Retrovir) and 
hydrochlorothiazide (Esidrix). 
2. Neonatal Candidiasis 
Overview 
Invasive candidiasis in neonates is a serious and relatively common cause of 
late onset sepsis associated with a high mortality. A review of the first 26 cases 
reported in the English literature up to 1984 reported a mortality rate of 54% 
(Johnson et al 1984). More recent data from the NICHD Neonatal Research Network 
centers reported a death rate of 28.1% in the neonates with fiingemia (Stoll et al 
1996). 
Premature neonates and particularly low birth weight infants require invasive 
diagnostic and aggressive therapeutic interventions, many of which increase the risk 
factors for developing Candida infections. In addition the immaturity of the immune 
system especially among- preterm neonates, which mainly involves T-cells and 
neutrophils, further predisposes this population to infections (Wilson 1986). Indeed. 
the anti-Candida activity of lung macrophages in neonates has been shown to be 
reduced (Bektas et al 1990; Frenkel et al 1987). 
Neonatal candidiasis can be subdivided into two categories: 
1. Catheter-related candidemia 
2. Disseminated or invasive candidiasis 
Catheter-related candidemia refers to infants with central vascular catheters in 
place and candidemia that resolves rapidly after catheter removal and initiation of 
therapy. Disseminated or invasive candidiasis refers to persistent candidemia if a 
catheter was in place and removed, and/or the isolation of Candida from other 
normally sterile body sites. However, as in adults, there are no clinical criteria or 
diagnostic tests that allow a differentiation of these two groups at presentation 
(Butler et al 1990). Up to 75% of cases of neonatal candidiasis present with infection 
of two or more organs. Unifocal osteomyelitis, meningitis, and renal candidiasis are 
the most common presentations, otherwise infection of any combination of blood, 
kidneys, meninges, heart, eye, (Johnson et al 1984). 
A distinctive form of cutaneous candidiasis that may become invasive and that is 
known as Congenital Candidiasis is discussed separately below. 
Epidemiology 
The incidence of invasive candidiasis in neonatal care units ranges between 
1.6 and 4.5% (Haley et al 1984b; Faix 1984; Johnson et al 1984). More recent data 
from the NICHD Neonatal Research Network centers on late-onset sepsis in ver> 
low birth weight neonates, has reported that fungal pathogens explain 9% of all 
bloodstream infections (StoU et al 1996).Neonates may acquire Candida by vertical 
or nosocomial transmission (Reef et al 1998; Waggnoner-Fountain et al 1996). In 
vertical transmission, acquisition may occur either during gestation or at the time of 
delivery. In both cases an ascending route from the mother's vagina is involved. 
Vaginal candidiasis occurs frequently among pregnant women, especially in the last 
trimester. Rates as high as 56% have been reported (French et al \911).Candida 
carriage rates among neonates vary between 30 to 60% (Pappu-Katikaneni et al 
1990). Interestingly as gestational age falls, the rates of candidal colonization appear 
to rise (Sharp et al 1992). Acquiring Candida does not always translate into systemic 
infection, but previous colonization is a required step before the step of occurrence 
of invasive candidiasis. 
Candidal nosocomial acquisition is being recognized as a very important 
form of transmission in the neonatal ICU (NICU) (Reef et al 1998). Indeed, 
important outbreaks of candidemia in NICU have been identified (Faix et al 1955; 
Finkelstein et al 1993; Reagan et al 1995). Such colonization is actually a general 
phenomenon: hand carriage rates among health workers in seven SICU across the 
USA have been found to be of around 30% (Rangel-Frausto et al 1999). 
Neonatal Candidiasis and Candida species 
Initial reports on neonatal candidiasis consistently found Candida albicans to 
be responsible for the majority of cases (Butler et al 1990; Faix et al 1989). 
However, similar to change of the epidemiologic patterns that has been observed in 
adults, a changing spectrum of species is being noted among neonates. This change 
is characterized by a progressive decrease in the rate of isolation of Candida 
albicans and an emergence oi xion-albicans species (Finkelstein et al 1993; Rangel-
Frausto etal 1999). 
Unlike the situation with adults however, it is Candida parapsilosis that is 
becoming the most prevalent species. In some centers it has replaced C albicans as 
the most frequent species (Levy et al 1998). 
Clinical Manifestations 
The classic clinical picture of systemic candidiasis in neonates is 
indistinguishable from bacterial sepsis (Baley et al 1984b). 
All of the following signs may be seen: 
Temperature instability hypotension, respiratory deterioration and 
apnea, abdominal distension, guaiac positive stools, carbohydrate 
intolerance. 
Among these, respiratory dysfunction and apnea were the most common 
presenting signs in large series, being present in about 70% of cases (van den Anker 
etall994). 
A significant proportion of neonates will present simultaneously with 
localized signs of candidal infection at one or more other sites: 
1) Skin and mucous membranes 
Mucocutaneous candidiasis in neonates may present with the classic thrush, diaper 
rash and/or any variety of this erythematous rash with papules and/or pustules 
affecting usually wet cutaneous surfaces (Faix et al 1989). Skin abscesses have also 
been described (Leibovitz et al 1992). However, the most common presentation is 
perineal candidiasis (Faix et al 1989). 
A. Oral candidiasis 
Oral candidiasis Angular cheilitis 
B. Candida skin and nail infections 
Candidal nail infection Superficial peeling from 
Candida infection 
Erosio interdigitalis 
blastomycetica 
Intertrigo Inflammatory Candida causing 
pustules 
Close-up of rash caused by 
Candida 
Fig. 1 Various Candida infections. 
Table. 3 Risk Factors for Neonatal Candidiasis 
Risk factors Comments References 
Classic (also described in adults) 
Use of multiple antibiotics 
Central venous catheters 
Parenteral hyperalimentation 
and intravenous fat emulsion 
Colonization with Candida 
and/or previous episode of 
mucocutaneous candidiasis 
Length of antibiotic treatment 
is as important as the 
spectrum of the regimen used 
-
-
-
(Weese-Mayer et al 
1987) 
(Weese-Mayer et al 
1987) 
(Weese-Mayer et al 
1987) 
(Faix etal 1989;Pappu-
Katikaneni et al 1990; 
Rowenetal 1994) 
Risk factors unique to this age group 
Low birth weight 
Endotracheal tubes and 
tracheostomies 
Peripheral venous catheters 
Congenital malformations, 
GI malformations and 
congenital heart diseases are 
the most frequent 
Gastrointestinal tract diseases 
~ 90% of affected neonates 
are very low birth weight 
(<I500gr) 
Many neonates have some 
type of respiratory 
insufficiency 
-
Most frequently seen in 
infants > 2,500 gr at birth 
with prolonged NICU 
hospitalization 
Necrotizing enterocolitis and 
anatomical abnormalities 
requiring surgery 
(Faix etal 1989) 
(Weese-Mayer et al 
1987) 
(Leibovitz 1992) 
(Rabalais et al 1996) 
(Faix etal 1989) 
It is important to emphasize that even when any of these forms of 
mucocutaneous candidiasis may precede the appearance of systemic disease; this is 
not a pathognomonic or required condition. Prospective evaluation of this 
association has foimd that 44% of neonates with invasive candidiasis never 
developed skin lesions (Faix et al 1989). However, the same analysis did 
demonstrate that neonates who developed mucocutaneous candidiasis had a higher 
risk of developing later deep organ candidal infection (Faix et al 1989). 
Two unique varieties of neonatal candidal skin diseases are: 
1. Cutaneous Congenital Candidiasis. This disease is discussed later. 
2. Invasive Fungal Dermatitis. This recently described skin disorder 
(Rowen et al 1995) affects extremely low birth weight neonates. 
Characteristic ulcerative and erosive lesions with extensive crusting are 
seen. Even when other fiingal pathogens have been implicated in this 
entity, Candida sp. is responsible for about 70% of cases (Rowen et al 
1995). More than half of these Candida-rtlaXed skin infections were 
associated with the occurrence of invasive candidiasis. Authors 
describing this picture and others have postulated that immature skin 
becomes in these cases the portal of entry for Candida (Rowen et al 
1995; Melville etal 1996). 
2) Central nervous system 
Among neonates Candida meningitis is one of the most common 
manifestations of invasive candidiasis (Baley et al 1984b; Chesney et al 1978; Faix 
1984). Up to 64 percent of neonates dying with invasive candidiasis have CNS 
involvement and more than 2/3 of these babies have positive CSF cultures at some 
point in their disease (Faix 1984). Neurologic clinical manifestations in this 
particular population are few and related to increased intracranial pressure (buldging 
fontanelle and splitting sutures). Instead, general signs of sepsis and progressive 
clinical deterioration are commonly found (Faix 1984). In other words, Candida 
meningitis usually presents as part of the syndrome of invasive or disseminated 
candidiasis. Therefore, a physician dealing with sepsis in a high risk neonate, should 
suspect Candida meningitis if Candida sp. is recovered from the blood, urine or 
other site suggestive of heavy colonization (Faix 1984). 
Candida meningitis carries a high rate mortality and for survivors a high 
incidence of severe sequelae (hydrocephalus, psychomotor retardation, and 
aqueductal stenosis) (Chesney et al 1978). 
3) Eyes 
The use of fundoscopic exam has been recommended as a tool for early 
diagnosis of invasive disease. The only prospective study evaluating neonates with 
either candidemia or CSF positive for Candida found an incidence of Candida 
endophthalmitis of 50% (Baley et al 1981). 
4) Heart 
Candidal endocarditis has been found to be the second most common form of 
endocarditis in this age group (Daher et al 1995; O'Callaghan et al 1988). Clinically, 
classic findings are expected, including cardiac murmurs, petechiae, skin abscesses, 
arthritis, hepatomegaly and splenomegaly (Daher et al 1995). Right-sided 
intracardiac fungal masses can manifest with heart failure or even with pulmonary 
fungal embolism (Johnson et al 1984; Gonzalez Dieguez et al 1992; Mayayo et al 
1996). 
5) Kidneys 
Candidal UTI is the most frequent cause of urinary tract infection in the 
NICU (Phillips et al 1997). About half of these babies are found to have concomitant 
candidemia (Phillips et al 1997). In addition, this population is particulariy 
predisposed to suffer renal candidiasis, which refers to renal fungus balls or renal 
fungal abscesses. Between 35 to 42% of neonates hospitalized at NICU with 
candiduria will have renal candidiasis, and the large majority of these cases are 
indeed fungus balls (Phillips et al 1997; Viscoli et al 1991). Unilateral or bilateral 
renal obstruction may occur (Phillips et al 1997; Viscoli et al 1991). Renal 
insufficiency could be the first clinical manifestation of invasive candidiasis (Visser 
etall998). 
6) Bones and Joints 
Candida sp. have been repeatedly listed among the three most common 
agents causing neonatal arthritis (Dan 1983; Omene et al 1984; Pittard et al 1976). 
Warmth and fusiform swelling of the lower extremities in combination with 
radiographic evidence of osteolysis and cortical bone erosion are the expected 
findings in cases of candidal osteomyelitis and/or arthritis in the neonate (Ward et al 
1979;Weisseetal 1993). 
Therapies 
The ways in which neonates differ in terms of relevant strategies are 
increasingly appreciated. Important differences on the pharmacokinetics but 
particularly on the toxicity profile of available antifungal agents have been 
demonstrated. As we will discuss, the both classic but toxic antifungal agents, 
amphotericin B and 5-fluorocytosine, cause minimal side effects in neonates and the 
combination of these two agents for the treatment of neonatal candidiasis has been 
extensively used and advocated (Baley et al 1984b; Duffy et al 1983; Faix 1984; 
Johnson et al 1984; Leibo.vitz et al 1992; Weese-Mayer et al 1987). 
1. Amphotericin B 
Initial reports on the use of amphotericin B in neonates were somewhat 
alarming. In particular, the report by Baley implicated this agent in a high mortality 
rate in 10 infants with invasive candidiasis and caused skepticism among 
neonatologists (Baley et al 1984a; van den Anker et al 1995). However, confounding 
factors such as previous renal insufficiency and the simultaneous use of other 
nephrotoxic agents were not considered (van den Anker t al 1995). 
Johnson (Johnson et al 1984) did not find a single case of significant renal 
toxicity with amphotericin B in a group of 21 infants (birth weight < 1,500 grams) 
with neonatal candidiasis treated with this agent. In addition, the classic infusion-
related side effects, fever, chills, nausea and vomiting are especially seen in this 
population (Johnson et al 1984; Duffy et al 1983; Ward et al 1983) and even when 
amphotericin B is known to inhibit erythropoietin production, anemia has not been 
described as a significant finding among babies treated with this drug (Butler et al 
1990; Lin etal 1990). 
Indeed, the use of amphotericin B alone for the treatment of neonatal candidiasis 
has been advocated by some authors, in view of the lack of an intravenous 
formulation of 5-fluoroc\tosine and the immaturity of the GI tract in neonates 
(Butler et al 1990). A retrospective analysis of such approach revealed that transient 
azotemia, elevations in serum creatinine and hypoalkemia occurred in about half of 
cases, but all these complications were satisfactorily managed with short 
interruptions of therapy or adjustment in dosing intervals. In addition, a comparison 
of the mortality rate of these infants treated without 5-fluorocytosine with the one 
reported by authors using the classic combination revealed they were similar or even 
lower (Butler et al 1990). 
2. 5-fluorocytosine 
Johnson (Johnson et al 1984) also emphasized the lack of cases of either bone 
marrow or liver toxicity when using 5-fluorocytosine for the treatment of neonatal 
candidiasis. They used doses of between 20 to 200 mg/kg/day. Many other reports 
reviewing this topic have favored the combined use of this agent with amphotericin 
B (Baley et al 1984; Johnson et al 1984; Leibovitz et al 1992; Weese-Mayer et al 
1987). 
3. Fluconazole 
Limited data on the use of fluconazole in this population has been published. 
Most of the data are from anecdotal reports (Bilgen et al 1995; Huan et al 1998; 
Krzeska et al 1993; Merchant et al 1997; Narang et al 1996; Viscoli et al 1989; 
1991; Wainer et al 1997). More recently a single randomized study compared 
fluconazole with amphotericin B for the treatment of 23 infants with neonatal 
candidiasis (Driessen et al 1996). However, a heterogeneous group of babies was 
included. Single stool culture positive for Candida was accounted as a criterion for 
invasive candidiasis in one case. Therefore, no major conclusions can be made from 
this study (Driessen et al 1996). There is no doubt that fluconazole deserves further 
evaluation. 
In conclusion, amphotericin B alone or in combination with 5-fluorocytosine 
remains the standard of care for neonatal candidiasis. The optimal duration of 
therapy is imknown. However, it is recommended to complete a minimun of 10 to 
15 mg/kg of amphotericin B in cases of uncomplicated catheter-related candidemia 
and between 25 to 30 mg/kg total for patients with invasive disease. When using 5-
fluorocytosine, 100 mg/kg/day given in four equal doses is recommended (Butler et 
all990). 
3. Chronic mucocutaneous candidiasis 
Overview 
Chronic mucocutaneous candidiasis (CMC) is the label given to a group of 
overlapping syndromes that have in common a clinical pattern of persistent, severe. 
and diffuse cutaneous candidal infections. These infections affect the skin, nails and 
mucous membranes. As suggested by Kirkpatrick's papers on this topic (Kirkpatrick 
et al 1971; 1976; 1979), the syndromes of CMC can be grouped as follows: 
Classification of Chronic Mucocutaneous Candidiasis (CMC) 
1. Chronic oral candidiasis 
o Related to denture stomatitis 
o HIV-associated candidiasis 
o Related to inhaled corticosteroid use 
2. CMC and polyendocrinopathy 
3. Localized CMC 
4. Diffuse CMC 
5. CMC with thymoma 
6. CMC with interstitial keratitis 
7. CMC associated with "KID" (keratitis, ichthyosis, deafness) 
While the causative factors in the oral syndromes in group 1 are easily 
understood, patients affected with the other forms of CMC usually have one or more 
associated underlying disorders. Endocrine dysfunctions are the most common 
association, but almost any organ system can be involved. Of note, CMC almost 
always remains limited to the skin. The rare reported cases of invasive fungal 
infection in patients with CMC have been candidal and cryptococcal meningitis 
(Germain et al 1994; Kauffman et al 1981). 
Immunopathogenesis 
However, the true details of the defect(s) associated with the various CMC 
syndromes remain poorly understood. For example, cytokine production has only 
recently been assessed in patients with CMC. In the one study on this topic, patients 
with CMC showed reduced or absent IL-2 secretion and increased IL-6 secretion 
(Lilic et al 1996b). This pattern suggests that patients with CMC have a Th2-like 
response rather than a Thl-like response. As a Thl-like response is important to 
control at least some candidal infections (Cenci et al 1995; Roman] et al 1991), 
demonstration of a Th2-like pattern in CMC is intriguing. In addition, some patients 
demonstrate abnormalities of antibody production and the susceptibility to viral and 
bacterial infections that is typical of antibody deficiency (Romani et al 1991). 
Hypogammaglobulinaemia associated with high levels of IgG and IgA antigen-
specific anti-Candida antibody has also been described (Lilic et al 1996a). 
Epidemiology 
CMC is rare, but data giving a good estimate of its frequency are not 
available. Ahonen (Ahonen et al 1990) registered all patients diagnosed with CMC 
in Finland between 1910 and 1988. During this 78 year period, these authors found 
only 68 patients with CMC in combination with either hypoparathyroidism or 
hypoadrenalism. There is also an Iranian Jewish population with at least a 
moderately high frequency of these syndromes (Bjorses et al 1996). Sporadic cases 
have been noted in many other regions of the world (Bjorses et al 1996). As 
discussed below, a specific gene has been linked to the variety of CMC noted in the 
Finnish and Iranian Jewish populations. 
Chronic mucocutaneous candidiasis is virtually always caused by Candida 
albicans (Kirkpatrick et all971). 
Clinical Manifestations 
Although CMC may become clinically apparent at any time in life, it 
typically presents before 3 years of age (Kirkpatrick 1989). Affected areas can be 
single or multiple and include the mouth, esophagus, nails, or skin (Kirkpatrick 
1989). 
Although the initial lesions are identical than the ones seen in the general 
population, over time patients with CMC characteristically develop unique 
disfiguring lesions (Kirkpatrick 1989). 
Chronic Oral Candidiasis 
This category is really quite distinct from all of the other forms of CMC. In 
the affected patients, persistence of well-known risk factors (either local or 
systemic) produces recurrent oropharyngeal candidiasis. 
CMC with Endocrinopathy 
This variety of CMC usually presents during infancy with persistent "diaper 
rash". Cutaneous candidiasis becomes more extensive later on, and onychomycosis 
also occurs. The endocrine dysfunctions can manifest any time during life, and 
usually follow a sequential pattern (Kirkpatrick 1993). 
Diagnosis 
From a diagnostic point of view, the evaluation of patients with suspected 
CMC is complex. Kirkpatrick has proposed the age-based approach to the patient 
(Kirkpatrick 1993). 
Therapy 
Current therapy for CMC principally revolves around prolonged use of 
antifungal agents. However, there have also been attempts to ameliorate the 
underiying immune defect of CMC. 
1. Antifungal Therapy: The availability of effective oral agents, especially the 
azole antifungal agents, has dramatically changed the life of patients living 
with CMC (Kirkpatrick 1994). Ketoconazole was the first agent to be 
extensively used for CMC and proved to be very successful when used either 
continuously or intermittently (Fanconi et al 1982; Graybill et al 1980; 
Herrod 1990; Horsburgh et al 1983; Kirkpatrick et al 1980; Mobacken et al 
1986; Montagnani et al 1986). However, liver toxicity soon was found to be 
a limitation (Tkach et al 1982). Itraconazole has also been used, although in 
fewer reports than for ketoconazole (Burke 1989; Tosti et al 1997). 
Fluconazole should also be effective, however there are only a few case 
reports describing its use (Hay et al 1988; Rybojad et al 1999; Shiraishi S et 
al 1994). 
2. Immunotherapy: Given the underlying immunologic nature of CMC. 
immunologic treatments of various sorts have been attempted in selected 
patients: 
o Thymus transplantation was associated with clearance of CMC in 
patients with DiGeorge syndrome and other severe deficiencies in 
cell-mediated immunity (Aiuti et al 1975; Cleveland et al 1968; 
Kirkpatrick et al 1976; Levy et al 1971). 
o White blood cell transfusions yielded transient relief in patients with 
CMC (Kirkpatrick et al 1971; Valdimarsson et al 1973). 
o Transfusion of a Candida-specific transfer factor has been reported to 
be very successful (remission for > 10 years) when combined with 
antifungal therapy (Ballow et al 1977; Kirkpatrick et al 1979). 
o Reports of successful treatment with bone marrow transplantation 
have also been published (Buckley et al 1968; Deeg et al 1986; Hoh 
etal 1996). 
4. Oral candidiasis 
Oral candidiasis is often known as thrush, because its white spots resemble 
the breast of the bird with the same name. Although Candida is present in 50% of 
healthy mouths, it causes infection when increased numbers of yeast cells invade the 
mucosa (the name for the moist skin inside body openings). 
Predisposing factors for infection include infancy or old age; serious 
underlying disease, such as cancer or infection with human immunodeficiency virus; 
dry mouth due to disease of the salivary glands or medications e.g. antihistamines, 
diuretics; dentures (especially if they are not regularly cleaned or fit badly); 
smoking; (Soysa et al 2005) injury to the mouth; nutritional deficiency e.g. iron &/or 
B-vitamin deficiency; inhaled corticosteroids used to treat asthma e.g. 
beclometasone, budesonide, fluticasone. (EUepola et al 2000; Taillandier et al 2000; 
Slavinsky et al 2002) 
5. Congenital Candidiasis 
Congenital candidiasis is a rare clinical entity in which intrauterine Candida 
infection becomes manifest at birth. Congenital candidiasis is not related to vaginal 
delivery, premature rupture of membranes, prematurity, maternal age and duration 
of labor or parity (Dvorak et al 1966; Rudolph et al 1977). Intrauterine contraceptive 
devices have been frequently associated with this condition (Darmstadt et al 2000; 
Delprado et al 1982; Whyte et al 1982). Two forms of disease have been described 
(Pradeepkumar et al 1998): 
1. Congenital cutaneous candidiasis 
In this case an extensive skin rash becomes manifest within the first 12 hours of 
life (Rudolph et al 1977), A macular erythema that may evolve from a pustular, 
papular or vesicular phase finally results in extensive desquamation (Rudolph et al 
1977; Glassman et al 1993). Paronychia and dystrophy of the nail plates have been 
also described Arbegast et al 1990; Raval et al 1995). The most commonly affected 
areas include the trunk, neck, face and extremities (Rudolph et al 1977). These 
cutaneous lesions usually resolve spontaneously or after short courses of oral 
nystatin (Rudolph et al 1977). 
2. Congenital systemic candidiasis 
In certain cases, the picture may evolve to an invasive infection and death, 
particularly in very low birth weight infants (Johnson et al 1981). This form of the 
disease has a high mortality rate. Importantly, at least half of the cases do not 
develop the cutaneous phase previously described (Jin et al 1995). Pneumonia with 
respiratory distress is the most common presentation of systemic or invasive 
candidiasis (Cosgrove et al 1997; Glassman et al 1993; Jin et al 1995; Whyte et al 
1982). Other presentations include candidal meningitis, candiduria and/or 
candidemia. 
Diagnosis 
Direct smear or culture of gastric aspirate, meconium, scrapings of skin 
vesicles or cord lesion can all be positive for Candida sp. Microscopic and even 
macroscopic examination of the placenta may disclose fungal Chorio-amnionitis 
(Whyte et al 1982). Elevated leukocyte count, with an increase in immature forms or 
persistent hyperglycemia are other frequently encountered findings (Darmstadt et al 
2000; Whyte etal 1982). 
Therapy 
Systemic antifungal therapy with amphotericin B is warranted in infants with 
skin lesions suggestive of congenital cutaneous candidiasis and respiratory distress 
(Mamloketal 1985). 
6. Balanitis 
Balanitis is an inflammation of the glans penis (head of the penis). 
Symptoms of balanitis include red swollen tender penis, blotchy rash may be 
present, occasionally penile discharge may be itchy and uncomfortable (Davis-
Daneshfar et al 2000). 
Causes of balanitis 
Balanitis is not a sexually transmitted disease. It is usually caused by irritants 
and an overgrowth of organisms that are normally present on the skin of the glans 
(English et al 1997). These include bacteria and Candida yeast. Certain 
circumstances may make a male more susceptible to getting balanitis, these include 
uncircumcised men, area under the foreskin is warm and moist, making it ideal 
conditions for the growth of organisms (usually Candida albicans) that cause 
balanitis; poor personal hygiene, diabetes, chemical irritants, e.g. soap, lubricating 
jelly; Obesity multiply and cause inflammation, particularly if the area under the 
foreskin is kept moist and uncleaned for a couple of days. (Sobel 1993) 
7. Fungal nail infections 
Fungal infection of the nails is known as Onychomycosis. It is increasingly 
common with increased age. It rarely affects children. Onychomycosis can be due to 
dermatophytes such as Trichophyton rubrum {T. rubrum), T. interdigitale. The 
infection is also known as tinea unguium (Williams 1993; Hay 2001). Candida 
infection of the nail plate generally results from paronychia and starts near the nail 
fold (the cuticle) (Williams 1993; Hay 2001). The nail fold is swollen and red, lifted 
off the nail plate. White, yellow, green or black marks appear on the nearby nail and 
spread. The nail may lift off its bed and is tender if you press on it. 
Antifungal drugs 
There are several classes of antifungal drugs (Dismukes 2000). 
1. Polyene antifungals 
A polyene is a circular molecule consisting of a hydrophobic and hydrophilic 
region. This makes polyene an amphoteric molecule. The polyene antimycotics bind 
with sterols in the fungal cell membrane, principally ergosterol (Gallis et al 1990). 
Animal cells contain cholesterol instead of ergosterol and so they are much 
less susceptible. (Note: by-reducing the hydrophobic chain on the polyene creates a 
more active sterol binding agent. Therefore, reducing the hydrophobic region too 
much results in binding to cholestenal, making it toxic to animals.) (Hiemenz et al 1996). 
2. Imidazole and triazole antifungals 
The imidazole and triazole antifungal drugs inhibit the enzyme Cytochrome 
P4S0 14 o-demethylase This enzyme converts lanosterol to ergosterol, and is 
required in fungal cell wall synthesis. These drugs also block steroid synthesis in 
humans (Hoesley et al 1997). 
Imidazoles: 
• Miconazole, Ketoconazole, Clotrimazole - marketed as Lotrimin or Lotrimin AF, 
Econazole, Bifonazole, Butoconazole, Fenticonazole, Isoconazole, Oxiconazole. 
Sertaconazole, Sulconazole, Tioconazole. 
The triazoles are newer, and are less toxic and more effective: 
• Fluconazole, Ravuconazole, Itraconazole, Posaconazole,Voriconazole, 
Terconazole. 
3. Allylamines 
Allylamines inhibit the enzyme squalene epoxide,and other enzyme required 
for ergosterol synthesis. 
Details of some common antifungals used 
Amphotericin B deoxycholate (AMB) 
Trade & Generic Names & General Features 
Amphotericin B is a polyene antifungal agent, first isolated by Gold et al 
from Streptomyces nodosus in 1955. It is an amphoteric compound composed of a 
hydrophilic polyhydroxyl chain along one side and a lipophilic polyene hydrocarbon 
chain on the other. Amphotericin B is poorly soluble in water (Terrell et al 1992). 
Amphotericin B is now available in four formulations. The clas.sic amphotericin B 
deoxycholate (FungizoneTM) formulation has been available since 1960 and is a 
colloidal suspension of amphotericin B. A bile salt, deoxycholate, is used as the 
solubilizing agent. 
amphotericin B 
COOH 
This preparation has a number of toxicities that are partially ameliorated 
when a lipid carrier is used. Thus, three lipid preparations of amphotericin B have 
been licensed and are currently available (Hiemenz et al 1996). These are: 
Amphotericin B Colloidal Dispersion (ABCD; Amphocil™ or Amphotec™); 
Amphotericin B Lipid Complex (ABLC; Abelcet'^ '^ ); Liposomal Amphotericin B 
(L- AMB; Ambisone™). 
Mechanisin(s) of Action 
Amphotericin B binds to sterols, preferentially to the primary fungal cell 
membrane sterol, ergosterol. This binding disrupts osmotic integrity of the fungal 
membrane, resulting in leakage of intracellular potassium, magnesium, sugars, and 
metabolites and then cellular death. The mechanism of action is the same for all the 
preparations and is due to the intrinsic antifungal activity of amphotericin B (Terrell 
et al 1992). 
Susceptibility Patterns 
A standard method of NCCLS is available for testing in vitro susceptibility 
to amphotericin B (National Committee for Clinical Laboratory Standards 1997; 
1998). However, it lacks ability to readily discriminate the resistant isolates from the 
susceptible ones. While some investigators have reported the use of Antibiotic 
Medium 3 to be useful in this respect (Lozano-Chiu et al 1998; Rex et al 1995b), 
data obtained in other studies do not always support this theory (Nguyen et al 1998). 
Using various modifications of the NCCLS methodology, moderately strong 
correlations between MIC and/or MLC (minimum lethal concentrations) and 
outcome have been reported (Nguyen et al 1998). 
Generally speaking, amphotericin B has a very broad range of activity and is 
active against most pathogenic fungi. Notable exceptions include Trichosporon 
beigelii (Walsh et al 1990); Aspergillus terreus (Sutton et al 1999); Pseudallescheria 
boydii (Walsh et al 1992); Malassezia furfur (Francis et al 1992) and Fusarium sp. 
(Arikanetal 1999). 
On occasion, however, isolate of any species may be found to be resistant. 
Among the Candida sp., isolates of C albicans, C. guilliermondii, C. lipolytica. C. 
lusitaniae, C. norvegensis, C. tropicalis, C. glabrata, and C krusei have been 
reported to be relatively resistant to amphotericin B (Karyotakis et al 1993; 1994; 
Meyer 1992; Terrell et al 1992). Reduced susceptibility has been observed 
specifically at fungicidal levels for C. parapsilosis (Seidenfeld et al 1983). 
Usual Doses 
Amphotericin B deoxycholate is administered by intravenous infusion at 
doses ranging from 0.3 to 1.5 mg/kg and over 1-4 h (Meyer 1992; Oldfield et al 
1990). 
Side-Effects 
The most commorily observed infusion-related side effects of amphotericin B 
deoxycholate are fever, chills, and myalgia. These can be partially overcome by 
premedication with diphenhydramine and/or acetaminophen (Goodwin et al 1985). 
Nephrotoxicity is the major adverse effect limiting the use of amphotericin B. The 
manifestations of nephrotoxicity are azotemia, decreased glomerular filtration, loss 
of urinary concentrating ability, renal loss of sodium and potassium and renal 
tubular acidosis (Meyer 1992). The renal injury reduces erythropoietin production 
and leads to a normochromic, normocytic anemia (Lin et al 1990). Thrombophlebitis 
may occur at the site of infusion. Thrombocytopenia may rarely be observed (Chan 
etal 1982). 
Routes 
Amphotericin B and its lipid formulations are administered intravenously. 
Current Status 
Amphotericin B still remains as the mainstay of antifungal therapy. Its lipid 
formulations, on the other hand, are promising due to their ability to reduce the 
toxicity of amphotericin B. They are currently licensed for use when amphotericin B 
therapy fails or is unacceptably toxic. The use of lipid formulations in specific 
clinical settings is under continuing investigation (Wong-Beringer et al 1998). 
Liposomal Nystatin 
Trade & Generic Names & General Features 
Liposomal nystatin is a lipid-based polyene antifungal agent. It is composed 
of nystatin incorporated into liposomes containing dimyristoyl phosphotidyl choline 
and di-myristoyl phosphtidyl glycerol. 
Aiming to reduce the systemic toxicity of nystatin, liposomal nystatin was 
first developed in 1987 by Lopez-Berestein (Mehta et al 1987; Wallace et al 1997). 
It is being manufactured by Aronex Pharmaceuticals under the generic name 
liposomal nystatin and the trade name Nyotran''"'^ . 
nystalin 
COOH 
\ \ ^ OH 
OH f'-"i^ 
Mechanism(s) of Action 
Similar to other polyene antifungal agents, nystatin binds to ergosterol in the 
fungal membrane. This binding disrupts osmotic integrity of the fungal membrane, 
resulting in leakage of intracellular potassium, magnesium, sugars, and metabolites 
and then cellular death. The lipid carrier of liposomal nystatin does not change this 
basic mode of action (Mehta et al 1987). 
Susceptibility Patterns 
When nystatin is incorporated into liposomes, its in vitro activity is 
maintained. Liposomal nystatin is active against a wide variety of yeasts and 
moulds, including Candida sp., Cryptococcus neoformans, and Aspergillus sp. 
(Jessup et al 1997; Mehta et al 1987). Comparison of nystatin and liposomal nystatin 
MICs produce variable results. Nystatin and liposomal nystatin MICs are either 
similar (Mehta et al 1987) or liposomal nystatin MICs are lower (Oakley et al 1999). 
The mechanism for generation of lower liposomal nystatin MICs is. not known, and 
some authorities feel that testing should simply be done using the parent compound 
alone (Nystatin). As for Amphotericin B and its lipid formulations, the in vitro 
susceptibility testing method for liposomal nystatin needs to be improved. 
Liposomal formulation enhances the activity of the drug by enabling the entrapment 
of the drug in reticulo-endothelial system and delivery of it specifically to the site of 
infection. Thus, the ultimate enhanced activity of lipid formulation compared to the 
parent compound nystatin, is probably not an outcome of enhanced "in vitro" 
activity but rather is that of improved efficacy "in vivo". Thus, the significance of 
susceptibility testing for liposomal nystatin is not known. 
Usual Doses 
In clinical trials done so far, liposomal nystatin has been intravenously 
administered at doses of 0.25 to 4 mg/kg (Williams 1999). Typical doses are not 
known yet. 
Side-Effects 
In contrast to nystatin, serious toxic reactions due to systemic administration 
of liposomal nystatin appear less likely. The most commonly encountered side effect 
is hypokalemia (Williams 1999). Nephrotoxicity also occurs, although details on the 
frequency of this side-effect are as yet unavailable (Williams 1999). 
Routes 
Liposomal nystatin is administered intravenously. 
Current Status 
Liposomal nystatin is in late Phase III clinical trials. Data obtained so far are 
promising for its future use in treatment of systemic fungal infections. 
Fluconazole 
Trade & Generic Names & General Features 
Fluconazole is a widely used bis-triazole antifungal agent. As with other 
triazoles, it has five-membered ring structures containing three nitrogen atoms. It is 
marketed as Diflucan® by Pfizer Pharmaceuticals (http://www.pfizer.com). Both 
oral and intravenous formulations of Fluconazole are available. 
OH F 
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Mechanism(s) of Action 
As with all azole antifungal agents, fluconazole works principally by 
inhibition of cytochrome P450 14 a-demethylase (P450 14 DM). This enzyme is in the 
sterol biosynthesis pathway that leads from lanosterol to ergosterol (Lyman et al 
1992 Marriott et all 987; Odds et al 1986). 
Fungal cell membrane synthesis is a multi-step process that involves the 
conversion of squalene to ergosterol. Fluconazole exerts its effect by selectively 
inhibiting the fungal cytochrome P450I4 a-demethylase. The result is a loss of 
normal fungal sterols and the accumulation of 14 alpha-methyl sterols within the 
fungus. 
Usual Doses 
For oropharyngeal candidiasis, and other forms of mucocutaneous 
candidiasis, fluconazole is typically dosed at 50-150 mg/day. For invasive 
candidiasis, the commonly applied dose is ~6 mg/kg/day, or 400 mg in the typical 
70 kg adult. Doses of ~12 mg/kg are not FDA-approved, but are used with 
increasing frequency due to the desire to achieve higher blood levels and thus extend 
the range of use of the drug. Even higher doses (up to 30 mg/kg in one report) have 
been used safely (Berry et al 1992; Anaissie et al 1995; Haubrich et al 1994; 
Menichetti et al 1996; Voss et al 1999). Fluconazole is excreted by the kidneys, and 
the dose should be reduced in proportion to any reduction of kidney function 
(Debruyne et al 1993). 
Epidemiology and Risk Factors 
Fluconazole is generally quite well tolerated. In common with all azole 
antifungal agents, fluconazole may cause hepatotoxicity. 
During the 1980s and 1990s, numerous reports emerged describing the 
development of fluconazole(Diflucan)-resistant oropharyngeal candidiasis in AIDS 
patients following prolonged exposure to fluconazole (Powderly et al 1999). During 
this time, the percentage of fluconazole-resistant Candida species ranged from 
approximately 5% to 33% (Powderiy et al 1999; Barchiesi et al 2002; Law et al 
1994). Investigators have identified low CD4 cell count, advanced immune 
suppression, greater number of fluconazole-treated episodes, and longer median 
duration of fluconazole therapy as the most important risk factors (Maenza et al 
1996; 1997; White et al 1998). With the widespread use of fluconazole for 
oropharyngeal candidiasis in the late 1980s, the proportion of C albicans isolates 
decreased and other Candida species, including C krusei, C. dubliniensis, and C. 
glabrata, increased. Fluconazole-resistant oropharyngeal candidiasis has involved 
both C. albicans and the non-albicans species. In recent years, clinicians have 
observed a major decrease in the number of patients with fluconazole-resistant 
oropharyngeal candidiasis, predominantly as a result of the widespread use of 
HAART (Martins et al 1998). 
Routes 
Fluconazole has both oral and intravenous formulations. 
Current Status 
Fluconazole is a very widely used antifungal agent. It is one of the first-line 
drugs, particularly in treatment of infections due to Candida spp. other than Candida 
krusei and some Candida glabrata isolates. Fluconazole is commonly used also for 
prophylaxis in transplant patients (Patel 2000; Wolff et al 2000). 
Itraconazole 
Trade & Generic Names & General Features 
Itraconazole (marketed as Sporanox® by Janssen Pharmaceutica) is a 
triazole antifungal agent that is prescribed to patients with fungal infections. The 
drug may be given orally or intravenously. 
Mechanism of action 
The mechanism of action of itraconazole is the same as the other azole 
antifungals: it inhibits the fungal cytochrome P450 oxidase-mediated synthesis of 
ergosterol. 
Indication 
Itraconazole has a broader spectrum of activity than fluconazole (but not as 
broad as voriconazole or posaconazole). In particular, it is active against aspergillus, 
which fluconazole is not. It is also licenced for use in blastomycosis, histoplasmosis 
and onychomycosis. Itraconazole is over 99% protein bound and has virtually no 
penetration into cerebrospinal fluid. Therefore, it should never be used to treat 
meningitis or other central nervous system infections (Gilbert et al 2006). According 
to the Johns Hopkins Abx Guide, it has "negligible CSF penetration, however 
treatment has been successful for cryptococcal and coccidioidal meningitis (The 
Safety Of Sporanox® Capsules And Lamisil® Tablets For The Treatment Of 
Onychomycosis 2001). 
Dosing 
Itraconazole is available as capsules or as an oral solution. The dose is 200 
mg once a day, to 400 mg in severe infection. There is an intravenous preparation 
available in the US, but not in the UK. In the UK, if an intravenous preparation is 
required, then an alternative antifungal drug should be used. 
The main problem with the use of itraconazole is its poor absorption, 
especially when given in capsule form. The oral solution is much better absorbed 
and should always be used in preference to the capsule. The cyclodextrin contained 
in the oral solution can cause an osmotic diarrhea, and if this is a problem, then half 
the dose can be given as oral solution and half as capsule in order to reduce the 
amount of cyclodextrin given. Itraconazole capsules should always be taken with 
food, as this improves absorption. Itraconazole oral solution should be taken an hour 
before food, or two hours after food (and likewise if a combination of capsules and 
oral solution are used). Itraconazole should be taken with orange juice or cola, as 
absorption is also improved by acid. Absorption of itraconazole is impaired when 
taken with an antacid, Ha-blocker or proton pump inhibitor. 
In life-threatening situations, some doctors give an oral loading dose of 200 
mg three times a day for three days, before dropping down to the usual dose. 
Because itraconazole absorption is unreliable, blood levels should be monitored at 
least once a week in those patients who are being treated for life-threatening (or 
potentially life-threatening) fungal infections. 
In intravenous dosing, four doses of itraconazole 200 mg are given 12 hours 
apart, before changing the dose to once daily. There is no safety data for giving the 
intravenous preparation for more than 14 days continuously. 
Adverse effects 
Itraconazole is a relatively well-tolerated drug (although not as well tolerated 
as fluconazole or voriconazole) and the range of adverse effects it produces is 
similar to the other azole antifungals. 
• Elevated alanine aminotransferase levels is found in 4% of people 
taking itraconazole. 
• "Small but real risk of developing" Congestive Heart Failure (The 
Safety Of Sporanox® Capsules And Lamisil® Tablets For The 
Treatment Of Onychomycosis 2001). 
The cyclodextrin that is used to make the syrup preparation can cause diarrhea. 
Side-effects that may indicate a greater problem include: 
• nausea, vomiting, abdominal pain, fatigue loss of appetite, yellow skin 
(jaundice), yellow eyes, itching ,dark urine, pale stool. 
Production, marketing and Consumption 
Itraconazole can be consumed orally in blue YB in (22 mm) capsules with tiny 
1.5 mm blue pellets inside. Each tablet contains 100 mg and is usually taken 
multiple times a day such as every twelve hours. Sporanox, the brand name of 
Itraconazole, has been developed and marketed by Janssen Pharmaceutica Products, 
L.P. a subsidiary of Johnson and Johnson. Apparently, the three layer structure of 
these blue capsules are quite complex because Itraconazole is insoluble and is 
sensitive to pH. Parts of the processes of creating Sporinox were discovered by the 
Korean Patent Laid. The contents of the capsule, the tiny blue pellets, are 
manufactured in Beerse, Belgium (www.Fresh Patents.com. 2004; Janssen 2006). 
Itraconazole is marketed as a treatment for at least three months and until test 
results find no fungal infections. It is also possible that Itraconazole treatment is 
prescribed indefinitely for some patients. Motivation to spend thousands of dollars 
for continued use is the risk and threat of the fungus regrowing in the body (Janssen 
2006). 
Clotrimazole 
Clotrimazole is an antifungal medication commonly used in the treatment of fungal 
infections of both humans and animals such as vaginal yeast infections and 
ringworm. It also used to treat athlete's foot and jock itch. 
General Information 
Lotrisone lotion has been approved by the FDA for the treatment of 
symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to 
Epidermophyton floccosum. Trichophyton mentagrophytes, and Trichophyton 
rubrum. Lotrisone contains two compounds - a synthetic corticosteroid 
(betamethasone dipropionate) and a synthetic antifungal agent (clotrimazole) - that 
target different aspects of fungal infection. Clotrimazole targets the cause of the 
infection by inhibiting the growth of fungus on the skin, whereas betamethasone 
reduces fungal infection symptoms such as itching, swelling, and redness. 
Mechanism of Action 
Clotrimazole is a broad-spectrum, antifungal agent used for the treatment of 
superficial infections caused by species of pathogenic dermatophytes, yeasts, and 
Malassezia furfur. The mechanism of action involves inhibition of the synthesis of 
ergosterol, a major sterol in the fungal cell membrane. This leads to instability of the 
cell membrane and eventual death of the fungus. 
Betamethasone dipropionate is a corticosteroid with anti-inflammatory, anti-
pruritic, and vasoconstrictive properties. The exact mechanisms of action of 
corticosteroids in each disease are uncertain; however, betamethasone dipropionate 
has been shown to have dermatological and systemic pharmacologic and metabolic 
effects characteristic of this class of drugs, (from Mosby, Inc.) 
Side Effects 
Side effects of Lotrisone may include (but are not limited to) the following:-
Blistering, Hives Infection, Irritated skin. Itching, Peeling, Skin eruptions 
and tingling sensation 
Less common side effects may include the following:-
Acne, burning, excessive hair growth and inflamed hair follicles 
Ketoconazole 
Trade & Generic Names & General Features 
Ketoconazole is an imidazole antifungal agent. As with other imidazoles, it 
has five-membered ring structures containing two nitrogen atoms. It is marketed as 
NizoraF"^ by Janssen Pharmaceutica (http://us.janssen.com/). Ketoconazole has oral 
tablet, cream and dandruff shampoo formulations. The oral formulation is available 
in USA since 1981. Ketoconazole is the only member of the imidazole class that is 
currently used for treatment of systemic infections. 
Ketoconazole is a highly lipophilic compound. This property leads to high 
concentrations of ketoconazole in fatty tissues and purulent exudates. Expectedly, 
the distribution of ketoconazole into cerebrospinal fluid is poor even in the presence 
of inflammation. Its oral absorption and solubility is optimal at acidic gastric pH 
(Sheehan et al 1999; van der Merr 1980). 
While ketoconazole was more widely used before the development of newer, 
less toxic, and more effective triazole compounds, fluconazole and itraconazole, its 
use has now been limited. It now appears as an alternative drug for specific 
indications. 
Mechanisni(s) of Action 
As with all azole antifungal agents, ketoconazole works principally by 
inhibition of cytochrome P45014 a-demethylase (P450I4 DM). This enzyme is in the 
sterol biosynthesis pathway that leads from lanosterol to ergosterol (Lyman et al 
1992). The affinity of ketoconazole for fungal cell membranes is less compared to 
that of fluconazole an itraconazole. Ketoconazole has thus more potential to effect 
mammalian cell membranes and induce toxicity (Como et al 1994). 
Susceptibility Patterns 
Ketoconazole is active against Candida sp., and Cryptococcus neoformans. 
However, its activity is limited compared to that of fluconazole and itraconazole (St-
Germain et al 1995). Furthermore, due to its limited penetration to cerebrospinal 
fluid, it is clinically ineffective in meningeal cryptococcosis. Its activity against the 
dimorphic moulds, Histoplasma capsulatum, Blastomyces dermatitidis, 
Coccidioides immitis, Sporothrix schenckii, Paracoccidioides brasiliensis, and 
Penicillium marneffei is favorable. However, fluconazole and itraconazole are at 
least as effective as ketoconazole against these fungi and are safer. Thus, 
ketoconazole remains as an alternative second-line drug for treatment of infections 
due to dimorphic fungi. Ketoconazole is not recommended for treatment of 
meningeal infections due to Histoplasma capsulatum, Blastomyces dermatitidis, and 
Coccidioides immitis due to its limited penetration to cerebrospinal fluid (Como et al 
1994). 
Ketoconazole is also active against Pseudallescheria boydii and is a good 
alternative for treatment of pseudallescheriasis (Sheehan et al 1999). It is also 
effective in pityriasis versicolor_(Degreef et al 1994). Ketoconazole has practically 
no activity against Aspergillus sp., Fusarium sp., and zygomycetes order of fungi 
(Como etal 1994). 
Usual Doses 
Oral ketoconazole is used at a dose of 200 to 400 mg/day in treatment of oral 
and chronic mucocutaneous candidiasis. The recommended dose is 400 mg/day in 
endemic mycoses due to dimorphic fungi in nonimmunosuppressed hosts (National 
Institute of Allergy and Infectious Diseases Mycosis Study Group 1985). The dose 
can be increased to 600-800 mg/day in patients not responding to regular doses. 
However, high doses carry the risk of high incidence of toxicity (Galgiani et al 
1988). 
Ketoconazole administered at a single dose of 400 mg/day is effective in 
treatment of pityriasis versicolor. The single dose therapy can be repeated once 
every month since recurrence is common with this infection (Degreef et al 1994). 
Side-Effects 
The major drawbacks of ketoconazole therapy are from the occasionally seen 
adverse reactions. It may induce anorexia, nausea and vomiting (Como et al 1994; 
Dismukes et al 1983). Increase in transaminase levels and hepatoxicity may occur 
Lewis et al 1994; Walsh et al 1991). Ketoconazole may decrease testosterone and 
Cortisol levels, resulting in gynecomastia and oligospermia in men and women 
irregularities in women (O'Connor et al 2002; Thompson et al 1993). 
The effects of ketoconazole on functions of the thyroid gland have also been 
investigated. There have been a number of reports suggesting that ketoconazole may 
have antithyroid function via impairment of thyroglobin iodination and 
iodothyrosine coupling. In vitro, ketoconazole has been found to form a complex 
with iodine and inhibit lactoperoxidase. In vivo experiments in rats have shown that 
the weight of thyroid gland increases in rats treated with ketoconazole (Comby et al 
1994). In another study designed to investigate the influence of ketoconazole on the 
basal and TSH-stimulated iodide uptake in the rat thyroid cells, concentration-based 
variations were observed. Ketoconazole appeared to increase the basal iodide uptake 
slightly at lower concentrations, while it sharply decreased the uptake below the 
basal levels at higher concentrations. Under TSH stimulation, the inhibitory effects 
of the drug were observed even at low concentrations (Kohan et al 1992). In contrast 
to these animal data, studies carried on in a limited number of euthyroid, healthy 
individuals, hypothyroid patients, and patients with thyrotoxicosis failed to provide 
any data suggesting a potential inhibitory effect of ketoconazole on thyroid functions 
(De Pedrini et al 1988). These data suggest that possible antithyroid effect of 
ketoconazole demands further investigation and close follow-up. 
Routes 
Ketoconazole has oral tablet, cream and dandruff shampoo formulations. 
Current Status 
Although an effective compound, ketoconazole has become a second-line 
drug due to the ready ayailibility of the somewhat safer agents, itraconazole and 
fluconazole. 
Interestingly, administration of ketoconazole has successfully decreased the 
serum ionized calcium and 1,25-dihydroxyvitamin D levels in two patients with 
tuberculosis-associated hypercalcemia (Saggese et al 1993). Also, ketoconazole has 
provided biochemical and hormonal improvement in patients with paraneoplastic 
Cushing's syndrome secondary to ectopic adrenocorticotropin (ACTH) production 
by malignant neoplasms (Winquist et al 1995). 
Definition of drug resistance 
Historically, clinical resistance has been defined as persistence or 
progression of an infection despite appropriate antimicrobial therapy. A successful 
clinical response to antimicrobial therapy typically not only depends on the 
susceptibility of the pathogenic organism but also relies heavily on the host immune 
system, drug penetration and distribution, patient compliance, and absence of a 
protected or persistent focus of infection (Galgiani et al 1987). 
Molecular mechanism of drug resistance 
Many different types of mechanisms are known to contribute to a drug-
resistant phenotype in eukaryotic cells. The most frequent resistance mechanisms 
include reduction in the import of the drug into the cell; modification or degradation 
of the drug once it is inside the cell; changes in the interaction of the drug with the 
target enzyme (binding, activity); changes in other enzymes in the same enzymatic 
pathway; and an increased efflux of the drug from the cell. 
Drug Import 
Defects in drug import are a common mechanism of drug resistance. 
However, it is important to emphasize the distinction between the import of a drug 
into a cell and the gradual accumulation of the drug in the cell, which is the result of 
a balance between import into the cell and efflux of the drug from the cell. Analysis 
of drug import is difficult at best and requires that mechanisms of import be 
separated from efflux mechanisms. The standard method for studying drug import is 
to determine the amount of drug that associates with cells in extremely short periods 
(less than 10 s). This method has been used extensively in studying drug import in 
parasitic protozoans (Hedstrom et al 1999). The short incubation periods are 
achieved by mixing the cells and the drug above a layer of mineral oil. After the 
short incubations, the cells are pelleted through the mineral oil and the amount of 
drug in the cell pellet is determined. 
Studies of fungi have usually used labeled drug to monitor the amount of 
label that accumulates within the cell over several minutes. These accumulation 
studies have led to the identification of several fungal efflux mechanisms (see 
below). One study with C. albicans suggested that accumulation of [^ H] 
ketoconazole required glycolytically derived energy and was controlled by cell 
viability, environmental pH, and temperature (Boiron 1987). This study also showed 
that ketoconazole accumulation at low extracellular concentrations was saturable, 
implying a specific facilitator of import, while accumulation at high concentrations 
appeared to be by passive diffusion. Curiously, this study found no evidence for 
export, since the addition of unlabeled drug did not lower the concentration of 
labeled drug in the cells. Finally, data in this study suggested that other azole drugs 
and amphotericin B increased the accumulation of labeled ketoconazole in the cell 
(Boiron 1987). These results are not easily explained by the currently understood 
molecular mechanisms, which include an energy-dependent efflux pump for 
fluconazole. The energy requirement for ketoconazole accumulation described in 
this study is inconsistent with the energy-requiring efflux mechanisms. Elimination 
of energy levels would inhibit energy-dependent efflux pumps, resulting in increased 
drug accumulation, the opposite of what is seen with ketoconazole. These results 
suggest that active transport may be involved in ketoconazole import. It is possible 
that the ketoconazole and fluconazole are imported by two different mechanisms. 
Drug import may also be affected by the sterol composition of the plasma 
membrane. Several studies have demonstrated that when the ergosterol component 
of the membrane is eliminated or reduced in favor of other sterol components such 
as 14a-methyl sterols, there are concomitant permeability changes in the plasma 
membrane and a lack of fluidity (Vanden Bossche et al 1987). These changes may 
lower the capacity of azole drugs to enter the cell. 
Another common mechanism of drug resistance is modification of the target 
enzyme and/or other enzymes in the same biochemical pathway. For azole drugs, 
that pathway is the ergosterol biosynthetic pathway. Analysis of the sterols of a cell 
can provide a wealth of information concerning the alterations that have occurred in 
a resistant strain. Modifications in the ergosterol pathway are likely to generate 
resistance not only to the drug to which the cells are exposed but also to related 
drugs 
Molecular Alterations of the ERG 11 Gene 
The predominant target enzyme of the azole drugs is lanosterol demethylase. 
The gene encoding this protein is currently designated ERG 11 in all fungal species, 
although it has previously been referred to as ERG 16 and CYP51A1 in C. albicans. 
Several genetic alterations have been identified that are associated with the ERG 11 
gene of C. albicans, including point mutations in the coding region, overexpression 
of the gene, gene amplification (which leads to overexpression), and gene 
conversion or mitotic recombination. 
A point mutation results in the replacement of arginine with lysine at amino 
acid 467 of the ERG 11 gene (abbreviated R467K, where R = Arg and K = Lys). The 
mutation is positioned near the cysteine which coordinates the fifth position of the 
iron atom in the heme cbfactor. The mutation is thought to cause structural or 
functional alterations associated with the heme (White 1997b). 
Common mechanism of resistance in eukaryotic cells is gene amplification. 
The increase in the number of gene copies usually results in an increase in 
expression. Overexpression of the ERG 11 genes in C. albicans has not been 
associated with amplification of the ERG 11 gene (Sanglard et al 1995; White 
1997a). However, in a clinical isolate of C. glabrata, increased levels of lanosterol 
demethylase were associated with a resistant phenotype (Vanden Bossche et al 
1992). These increased levels of the protein were associated with ERGII gene 
amplification (Marichal et al 1997; Vanden Bossche et al 1994a) and correlated with 
an increase in ERG 11 mRNA levels (Vanden Bossche et al 1994b). In the same 
isolate, changes in drug efflux and in ERG7 activity were also observed (Vanden 
Bossche et al 1994a). After 159 subcultures, the gene amplification, increased 
mRNA levels, enzyme levels, and drug efflux all reverted to normal. However the 
revertant retained partial resistance to fluconazole (Vanden Bossche et al 1994a). 
Recently, gene amplification of ERG 11 in this isolate has been linked to a 
chromosome duplication, which results in overexpression of ERGll, as well as 
altered expression of a variety of other proteins (Marichal et al 1997). 
Two Major Types of Efflux Pumps 
Eukaryotic cells contain two types of efflux pumps that are known to 
contribute to drug resistance: ATP binding cassette (ABC) transporters (ABCT) and 
major facilitators (MF) (Marger et al 1993; Michaelis et al 1995). Both types of 
pumps are known to cause drug resistance in other systems. The ABCT are 
frequently associated with the active efflux of molecules that are toxic to cells and 
are relatively hydrophobic or lipophilic, as is the case with most azole drugs. The 
MF has not been studied as extensively as the ABCT but is also associated with 
relatively hydrophobic molecules such as tetracycline (Marger et al 1993). 
The ABCT are composed of four protein domains: two membrane-spanning 
domains (MSD), each consisting of six or seven transmembrane-spanning segments, 
and two nucleotide binding domains (NBD) (Michaelis et al 1995). The NBD of 
ABCT bind ATP through an ABC that consists of several conserved peptide motifs, 
including two Walker domains, a Signature domain and a Center domain. The ATP 
that is bound to the ABC is used as a source of energy for the ABCT, although the 
mechanism by which the ATP energy causes transport of the substrate molecule is 
unknown. 
The MF does not contain NBD. They are composed primarily of 12 to 14 
transmembrane segments (Marger et al 1993; Paulsen et al 1996). The MF uses the 
proton motive force of the membrane (gradient of H"^  across the membrane) as a 
source of energy. In general, the MF work by antiport; that is, protons are pumped 
into the cell and substrate molecules are pumped out. 
Recently, the complete sequencing of the genome of S. cerevisiae has 
allowed a determination of the total number of ABCT and MF in the genome of a 
eukaryotic cell. Thirty ABCT genes that contain an ABC have been identified 
(Taglicht et al). Twenty-three of these genes appear to encode a transmembrane 
segment, which suggests that they could function as drug pumps and are closely 
related to known ABCT drug pumps. Twenty-eight MF genes were also identified in 
the S. cerevisiae genome by homology to the five known MF genes of fungi (Goff et 
al 1995). This suggests that S. cerevisiae contains at least 51 different genes 
encoding efflux pumps that could contribute to the drug resistance levels of the cell. 
There is good reason to believe that Candida and other fungi would have a similar 
number of efflux pumps in their genomes 
Chapter-2 
Materials & Methods 
Media and reagents used ; 
Steam sterlization of the prepared media, buffers and reagents was done. The 
following were the conditions: 
Pressure : 151b/sq inch 
Temperature :121 C 
Time : 15 minutes 
Media : 
1. Corn Meal Agar: 
Com meal 
Infusion from agar 
2. Saboraud Dextrose Agar 
Peptone special 
Dextrose 
Agar 
3. HiChrome Candida Differential Agar 
Peptone special 
Yeast extract 
Dipotassium hydrogen phosphate 
Chromogenic mixture 
Chloramphenicol 
Agar 
4. Yeast Peptone Dextrose 
Yeast extract powder 
Peptone 
D-glucose 
50g/l 
15g/l 
lOg/1 
20g/l 
17g/l 
15g/l 
4g/l 
lg/1 
7.22g/l 
0.5g/l 
15g/l 
lOg/1 
lOg/1 
20g/l 
Reagents : 
Mac. Farland Reagent 
H2SO4 0.18M (99.5ml) 
BaCh 0-048M (0.5ml) 
Methods : 
Collection of samples; 
The present study was conducted for a period of 1 year 4 months from Nov. 
2005 to March 2007 on samples isolated from Jawaharlal Nehru Medical College 
(JNMC) & Hospital, AMU and Feroz Specialist Hospital & Research Center ( 
FSHRC), Aligarh. 
A total of 1470 vaginal yeast cultures were collected from pregnant ladies in 
the labour room and from Gynaecology OPD of JNMC and FSHRC. Out of 1470 
samples 600 samples were showing signs and symptoms of the disease. Of these 
600 samples, only 175 samples were positive for Candida. From these 175 posative 
samples 200 Candida isolates were obtained. 
A total of 1825 samples were collected from NICU, JNMC, AMU Aligarh. 
Out of 1825 samples 500 samples were showing signs and symptoms of the disease. 
Out of these 500 samples only 138 samples were positive for Candida. From these 
138 posative samples 150 Candida isolates were obtained. These isolates were 
subjected to undergo morphological and biochemical identification and 
characterisation was further done. Clinical data such as age, sex, site of infection 
predisposing factors, history of exposure to antifungals and clinical out come of the 
patients are noted and shovm in tables. 
Morphological tests 
1. Lactophenol Cotton Blue (LPCB) 
Place a drop of lactophenol cotton blue (LPCB) on a clean glass slide with a 
dissecting needle, remove a small portion of the colony to be examined from agar 
surface and place it in the" drop of LPCB.With two dissecting needles, gently tease 
apart the mycelial mass of the colony on the slide. Observe under microscope, first 
lf)w power and then high power (Larone 1995). 
Comparatively large and oval cells as compared to the small, round bacterial 
ceils are distinguished . Pseudohyphae is also seen in case of yeast cell (San-Millan 
•:tal 1996). 
2. KOH Preparation 
Most organic substances that might be confused with fungi when seen 
through the microscope are converted to almost clear background in the presence of 
moderately strong alkali solutions. The fungi remain unaffected and are therefore 
easily demonstrated. 
Some of the specimen is placed is placed on a glass slide with 1-2 drops of 
10%KOH. A coverslip is placed over the mixture and this slide is treated gently 
over a flame and then removed just before the mixture reaches the boiling point 
n,arone 1995). 
3. Gram Staining 
Fix the smear by passing it o\er a flame. Place crystal \iolet solution on the 
slide for 20 seconds. Wash gently in tap water. Decolorize quickly in solution of 
equal parts of acetone and 95% ethanol.Wash gently in tap water . Counterstain in 
Safranin for 10 second. Wash with tap water and air dry it. Observe the colour. 
A purple color is a positive test for Candida (Larone 1995). 
4. Corn Meal Agar 
Commeal with Tween 80 is used in distinguishing the different species of 
Candida. A quarter of the plate is used for each organism. A hard streak is made 
around the centre of the areas (slightly cutting the agar) and three or four soft streaks 
across the first one. Cover with a 22 X 22 coverslip and incubate at room 
temperature for three days.The plate without its lid is placed on the microscope. 
Different colonies show different morphology on CMA and they can be identified 
from the standard (San-Millan et al 1996). 
5. Germ Tube Test 
One of the most valuable and simplest tests for the rapid, presumptive 
identifications of Candida albicans. Using a capillary pipette, a portion of the yeast 
colony is emulsified in 0.5 ml of Fetal Bovine Serum. The preparation is incubated 
at 37 °C. A drop of serum is examined microscopically for the presence of 
germtubes (Larone 1995). 
6. CHROM Candida Agar. 
The media is dissolved in autoclaved distilled water. The conical flask with 
media in it is boiled on heater, cooled to 50 ''C and poured in autoclaved 
petriplates.The specimen is then streaked on the solified plates.kept at 37 "C for 48 
hours. Different species show colonies of different colour (Odds et al 1994). 
Biochemical tests 
1. Carbohydrate Fermentation Test 
Fermentative yeasts recovered from clinical specimen produce CO2 and 
alcohol. Production of gas and not a pH shift is indicative of fermatation. The test is 
done in tubes containing Durham tube inserts (small inverted tubes that trap CO2. 
An aqueous suspension of yeast not exceeding a density of a Mac Farland standard 
is prepared and 0.1 ml is added to each of the fermentation broth tubes. The tubes 
are incubated at 30°C for 10-14 days,agitated daily. Positive fermentation is 
evidenced by gas bubbles being trapped in durham tubes. Carbohydrates used are 
dextrose, maltose, sucrose, galactose, lactose and trehalose (Larone 1995). 
2. Carbohydrate Assimilation Test 
It measures the ability of a yeast to utilize a specific carbohydrate as the sole 
source of carbon in the presence of oxygen. Each tube is inoculated with a very 
dilute suspension of yeast cells with a very dilute suspension of yeast cells and 
incubated at room-temperature for 21 days. Assimilation is detected by the presence 
of growth (turbidity) in each tube. The major advantage is flexibility. Many more 
carbon sources in addition to the 12 standard can be tested (Salkin et al 1998). 
Antifungal susceptibility testing by Disc Diffusion method 
All the 350 positive Candida isolates were tested on Sebaraud Dextrose Agar 
for their sensitivity against six antifungals namely Amphotericin-B, Nystatin, 
Clotrimazole, Itraconazole, Fluconazole and Ketoconazole. 
5 ml of sterilized SDA broth were poured into autoclaved, plugged test tubes 
and each tube inoculated with positive samples of Candida. The inoculated tubes are 
then kept in incubator at 37''C for 24 hours. Each inoculum is then spread over 
solidified SDA plates .Sterlized forceps were then used to apply antifungal discs and 
the sensitivity plates were incubated overnight at ST^C. The sensitivity was 
monitered by visualizing the zone of inhibition around the disc (Bauer et al 1996). 
Table No. 4: List of Antifungals used 
Antifungal 
Amphotericin-B 
Clotrimazole 
Flucanazole 
Itraconazole 
Ketoconazole 
Nystatin 
Symbol 
Ap 
Cc 
Fu 
It 
Kt 
Ns 
Concentration 
100 unit 
10 meg 
10 meg 
10 meg 
10 meg 
100 meg 
Diameter of zone 
of Inhibition 
10-18 
12-18 
18-22 
18-22 
18-22 
15-23 
Chapter-S 
Isolation. Characterization & 
Drug Resistance Pattern of 
Candida Species Isolated from 
Patients Attending 
Gynecology OFD. 
3.1 Introduction: 
Limited data addresses the incidence of vulvovaginal Candidiasis. It suggests 
that approximately two-thirds of women experience at least one episode during their 
lifetime and nearly 50% of women have multiple episodes (Berg et al 1984; 
McCormack et al 1994).Although the majority of cases of vulvovaginal candidiasis 
are caused by C. albicans; however, episodes due to non-albicans species of 
Candida also appear to be increasing (Ozacan et al 2006, Kuriyama et al 2005; Sobel et 
al 1997; Cheng et al 2006). Most non-albicans Candida species have higher azole 
MICs, and infections caused by the non-albicans are often difficult to treat (Antunes et 
al 2004, Ostrosky et al 2003; Ribeiro et al 2000; Singh et al 2002; Sobel et al 1993). 
A possible explanation for more frequent isolation of non-albicans species 
from vulvovaginitis patients may be the increased use of topical azole agents 
(Nyirjesy et all997; Marcia et al 2004). Patients who see a physician usually receive 
empirical therapy; vaginal cultures are not routinely obtained, and susceptibility 
testing is rarely performed. 
Surveillance programs for candidemia have demonstrated that fluconazole 
resistance among C. albicans bloodstream isolates is rare (Pfaller et al 2002). It is 
analyzed that yeast isolates from vulvovaginitis patients have also shown the 
recovery of fluconazole-resistant C. albicans isolates to be an unusual event (Arzeni 
et al 1997; El-Din et al 2001; Antunes et al 2004, Ostrosky et al 2003; Ribeiro et al 
2000; Sobel et al 2004), but they often have included a small number of isolates. The 
increased use of over-the-counter antiftingals and prolonged therapy for recurrent 
candidiasis are risk factors for the emergence of azole resistance among C. albicans 
isolated from vulvovaginitis patients. 
The purpose of this study was to determine the species distribution and 
prevalence of antifungal resistance among a large collection of Candida species 
isolates from patients with Vaginal Candidiasis. 
There is mounting evidence suggesting that Candida bloodstream infections 
(BSI) have become a major problem in tertiary-care hospitals worldwide (Almirante et 
al 2005, Marchetti et al 2004, Pappas et al 2003, Tortorano et al 2004). Candidemia is 
generally difficult to diagnose and hard to treat, has a high attributable mortality rate, 
and is costly (Gudlaugsson et al 2003, Morgan et al 2005). 
3.2 Material and methods: 
The present study was conducted for a period of 1 year 4 months from Nov. 
2005 to March 2007 on samples isolated from Jawaharlal Nehru Medical College 
(JNMC) & Hospital, AMU and Feroz Specialist Hospital 8c Research Center ( 
FSHRC), Aligarh. 
A total of 1470 vaginal yeast cultures were collected from pregnant ladies in 
the labour room and from Gynaecology OPD of JNMC and FSHRC. Out of 1470 
samples 600 samples were showing signs and symptoms of the disease. Of these 
600 samples, only 175 samples were positive for Candida. From these 175 posative 
samples 200 Candida isolates were obtained. Lactophenol Cotton Blue (LPCB) , 
KOH & Gram staining slides were made of all the isolates to differentiate between 
yeast and bacteria.All the isolates having yeast like cells were plated on HiChrome 
Candida Differential Agar (Hi-Media chemicals, India), to ensure the detection of 
mix infections.Culture were incubated at 37 °C for 48 hrs.AU the C.albicans show 
green colony on HiChrome Candida Differential Agar and they were further 
confirmed by the GTT(Germ Tube Test). GTT is posative for C.albicans only. For 
further morphological identification rest of the cltures were plated on Com Meal 
Agar (Hi-Media chemicals, India). Furthur confirmation was done by sugar 
assimilation and sugar fermentation tests. 
All the 200 positive Candida isolates were tested on Sebaraud Dextrose Agar 
for their sensitivity against six antifimgals namely Amphotericin-B, Nystatin. 
Clotrimazole, Itraconazole, Fluconazole and Ketoconazole. 
5 ml of sterilized SDA broth were poured into autoclaved, plugged test tubes and 
each tube inoculated with positive samples of Candida. The inoculated tubes are then 
kept in incubator at 37°C for 24 hours. Each inoculum is then spread over solidified 
SDA plates .Sterlized forceps were then used to apply antifiingal discs and the 
sensitivity plates were incubated overnight at 37°C. The sensitivity was monitered 
by visualizing the zone of inhibition around the disc (Bauer et al 1996). 
3.3 Results: 
This study was done on 200 isolates from 175 samples isolated from the 
1490 patients attending gynecology OPD.Out of 200 isolates 129 (64.25 %) were C. 
albicans ,38 (19 %) were C. glabrata, 14 (7 %) C. parapsilosis , 10 (5 %) C. 
tropicalis , 6 (3 %) C. krusie , 3 (1.5 %) C. kyfer (Table 4 , table 5.1 , table 5.2). 
More comprihensive picture of % occurrence of each Candida specieswas shown in 
fig.3. Distribution of Candida species In different cultures with respect to age group 
of women is shown in table 6. Out of 175 women with posative Candida culture 20 
(11.43 %) had the multiple positive cultures. From these 20 cultures , 45 Candida 
isolates were isolated. There are 155 cultures having single species 155 Candida 
species were isolated from these cultures. Out of 155 Candida isolates 113 (72.90 %) 
were C. albicans. The % of C. albicans in cultures having single species was higher 
than the % of C. albicans in total 200 (72.90 % vs 64.25 %). The age of the women 
at the 1^ ' visit to gynecology OPD ranged from 15 years to 74 years. The maximum 
C. albicans infection was found in the women of age 15-54 years.The total patients 
in this age group were 163. Out of 163 patients C. albicans was isolated from 120 
patients (73.61 %). 24 C. glabrata were isolated from 155 cultures. The % of C. 
glabrata in culture having single species was lower (15.48 %) than the % in total 
200 Candida isolates (19 %). The maximum C. glabrata infection was found in 
women of age group 15-24 years, followed by 25-34 years. The total patients in this 
age group were 93. Of 93 patients, 26 patients were found to have C. glabrata 
(27.96 %). Total patients in age group of 35-44 years were 36. Out of 36 , C. 
glabrata was isolated from 7 patients (19.44 %). 5.71 % infections of C. glabrata 
was found in the women of age group (45-54 years). 16.67 % of C. glabrata 
infection was found in older women (55-67 years). No C. glabrata infection was 
found in the women of age group, 65-74 years (table 6). 
Out of 155 cultures having single species 9 strains of C. parapsilosis were 
isolated (5.88 %).Which is lower as compared to total 200 Candida isolates (7%). 
The maximum C. parapsilosis infection was found to be more prevalent in women 
of young age (15-24 years). The total patients in this age group were 56. Out of 56. 
C. parapsilosis was isolated from 7 patients (12.5 %) folowed by 8.11 % among 
women of age group 25-34, 5.66 % in women of age group 35-44, 2.86 % in 45-54 
age group women. No C. parapsilosis infection was found in the older women (55-
74 years). 2 C. tropicalis were isolated from 155 cultures having single 
species(1.29%). It was lower than the % of C. tropicalis in total 200 cultures (1.29 
% vs 5 %). Maximum (10.81 % ) , C. tropicalis in fection was found in the women 
of age goup 25-34 years. 8.93 % C. tropicalis infection was found in women of age 
group 15-24 years. 5.56 % C. tropicalis infection was found in women of age group 
35-44 years. No C. tropicalis infection was found in the women of age group 45-74 
years. % of C. krusie in cultures having single species is slightly higher (3.23%) 
than the % of C. krusie in total 200 isolates (3 %). Maximum (8.1 %), C. krusie 
infection was found in the women of age goup 25-34 years. 3.57% C. krusie 
infection was found in women of age group 15-24 years. 2.78 % C. krusie infection 
was found in women of age group 25-34 years. No C. krusie infection was found in 
the women of age group 45-74 years. % of C. kyfer in cultures having single species 
is slightly higher than the % of C. kyfer in total 200 isolates (3.57 % vs 2.70 %). No 
C. l^fer infection was found in the women of age group 35-74 years. The % of non-
albicans in total 200 isolates was slightly higher than the % of non-albicans in the 
cultures having single species(35.5 % vs 27.09 %). 15 out of 175 (8.57 %) patients 
were having infection with two species A total of 30 Candida isolates were yielded 
from these 15 cultures. Out of 30 isolates 11 isolates were C. albicans (36.67 %). 
The % of C. albicans in cultures having two species is lower (36.67%)) than the % 
of C. albicans in cultures having single species (36.67 % vs 72.90 %), and % of C. 
albicans was quite less than the % of C. albicans in total 200 isolates (36.67 % vs 
64.25 %)). Out of 30 isolates total non-albicans were 19 (63.33 %). It was quite 
higher than the % of non-albicans in culture having single species (63.33 % vs 
27.09 %.) and the % non-albicans in total 200 isolates (63.33 % vs 35.5 %). Out of 
15 cultures having two species 5 were having C. albicans and C. glabrata, 3 C. 
albicans and C. tropicalis, 2 C. tropicalis and C. glabrata, 2 C. glabrata and C. 
parapsilosis, 1 C. albicans and C. kier, and 1 C. albicans C. krusie. Out of 175 total 
cultutres, there were 5 cultures having three speciesTotal isolates from these cultures 
were 15. Out of 15 isolates 5 were C. albicans (33.33 %>). The % of C. albicans in 
total 200 isolates (33.33 %>) was nearly half the % of C. albicans in culture having 
single species (64.25 %). The % of C. albicans in culture having three species( 
33.33 %) was quite less than the % of C. albicans in culture having single species( 
72.90 %).% of C. albicans in culture having three species (33.33%) is slightly less 
than the % of C. albicans in culture having two species( 36.67%). % of non-albicans 
in cultures having three species was 66.67 %. It was quite higher than the % of non-
albicans in total 200 isolates (35.5 %), it was higher than the % of non-albicans 
culture having single species (27.09 %) and it was slightly higher than the % of non-
albicans in cultures having two species (63.33 %). More comprihensive picture of % 
occurence of each species of Candida in different cultures is shown in (Table 7). 
Majority of C. albicans ,C. glabrata, C. parapsilosis were isolated from 
culture having single species as compared to culture mixture of two species and 
culture mixtuture of three species But in case of C. tropicalis majority were isolated 
from culture having two species(50 %) followed by culture having three species (30 
%) and least from culture having single species (20 %). Majority of C. krusie and C. 
kyfer were isolated from culture having single species(83.33 %, 66.67 % 
respectively). No C. krusie and C. kyfer were isolated from culture having three 
species(table 8). 
Every patients with multiple Candida isolates reported at least one of the 
symptoms like vulvovaginal itching, vulvovaginal pain, vulvovaginal discgarge. 
Every patients with vaginal candidiasis had at least one of the medical condition 
listed in (table 8), noted in their clinical profile on her visit to gynecology OPD. Out 
of 175 majority (57 %) of the patients had vulvar contact dermatitis, urinary tract 
infections (30 %), diabetes (25 %), Vulvar Intraepithelial Neoplasia (VIN) (24 %) 
vulvar vestibulitis (20 %), hormon replacement therapy (10 %), chronic sinussitis (4 
% ), acne (3 %) , CIN (2.5 %) and urinary incontinence (1.5 %). Most of UTI 
infections were found in women of age group (45-54 years) followed by 25-34 
years (12 out of 60), chronic sinusitis was found commonly in women of age group 
15-24 years (5 out of 8), no chronic sinusitis was found in women of age group 55-
74 years. Majority of acne was found in women of age group 15-24 years (5 out of 
6), no acne was found in women of age group 35-74 years. Majority of contact 
dermatitis was found in women of age group 45-54 years (5 out of 6), followed by 
35-44 years and least was found in 55-74 years. It was found that vulvar vestibulitis 
was found in women of age group 15-24 years (20 out of 40 years), and no results 
were found in women, of age group 55-74 years. VIN was most common in women 
of age group 35-44 years (15 out of 48) folowed by 45-54 years (12 out of 48). Least 
was found in age group 65-74 years. Lichen sclerosis was most common in women 
of age group 15-24 years (8 out of 20). No case was found in women of age group 
55-74 years. Diabetes was most common in women of age group 45-54 years (11 out 
of 25) and least in women of age group 15-24 years (1 out of 25). CIN was also most 
common in women of age group 45-54 years (3 out of 5). No case was found in 
women of age group, 15-34 and 65-74 years. Urinary incontinence was found equaly 
in all women of age group 35-64 years and no case have been detected among the 
women of age group 15-34 and 65-74 years. Hormon replacement therapy was most 
common in women of age group 45-54 years (10 out of 20), followed by 55-64 years 
(8 out of 20). No case was found in women of age group 15-44 years (table 8). 
Most of strains were isolated from vagina as compared to cervical ( 70 %) 
including C. krusie (5 out of 6 ; 83.33 %), followed by C. glabrata (73.68 %). Other 
species were also predominantly isolated from vagina, compared to cervical, (table 
10) Candida infection was found more prevalent among pregnant women as 
compared to non-pregnant women (55 %). % occurrence of C. albicans, C.glabrata, 
C. parapsilosis during pregnancy was higher than the % occurrence in non-pregnant 
women (55.81 % vs 44.74 %, 55.20 % vs 44.74 % , 64.29 % vs 35.71 % 
respectively). C. krusie was found to be present equaly among pregnant and non-
pregnant women. Where as C tropicalis and C. kier were isolated maximaly among 
non-pregnant women (60 % vs 40 %). 
Susceptibility test for each species are shown in (table 11). Susceptibility 
testing was performed using disc diffusion method. Our results revealed that 63 % 
isolates were resistant against Itraconazole, followed by Ketoconazole (46 %), 
Fluconazole (20 %), Nystatin (17 %), Clotrimazole (16.5 %) and Amphoteric in-B 
(7.5 %). More comprehensive picture is shown in (fig. 17). Itraconazole resistance 
was observed maximum in C. glabrata (78.95 %), followed by C. albicans (62.01 
%), C .parapsilosis (50%), C. tropicalis (50 %), C. krusie (50 %) and least in C, 
kyfer (33.33 %). Ketoconazole resistance was observed maximum in C. glabrat 
(52.63 %), followed by C. albicans (46.51 %), C .parapsilosis (42.86 %), C. krusie 
(33.33 %), C. kyfer (33.33%) and least C. tropicalis (30 %). Nystatin resistance was 
observed maximum in C. albicans (23.26 %) followed by C. tropicalis (10 %) and 
least in C.glabrata (2.33 %), no resistance was observed in C .parapsilosis, C. 
krusie, C. ^/er. Maximum Clotrimazole resistance was observed maximum in C. 
albicans (23.26 %) followed by C. glabrata (2.23 %). 
Maximum Fluconazole resistance was observed in C. krusei (66.67 %) 
followed by C .tropicalis (21.43 %), C. Arw^ /e (20 %), C. fl/6/ca«5 (19.38 %). No 
resistance against Fluconazole was observed in, C. krusie, and C. glabrata. 
Maximum Amphotericin-B resistant was observed in C .parapsilosis (21.43 %), 
followed by C. glabrata (15.79 %), C. tropicalis (10 %), and C. albicans (3.88 %). 
C. ArM5/e(l %). No resistance against Amphotericin-B was observed in C. kyfer. 
Table 4: Etiology and characterization of Candida species based on the 
morphology. 
Total no. 
Candida 
species 
isolated 
%of 
total 
isolates 
C. albicans 
64.5% 
(129) 
Morphology 
on KOH slide 
Round, oval, 
big, yeast like 
cells, 
budding cells 
Morphology on 
Hi- chromo 
Candida agar 
Micro scopic 
morphology on 
CMA at 37°C 
Green 
Pseudohyphae 
with terminal 
chlamydospores; 
clusters of 
blastospores at 
septa 
Growth 
on ZfC 
onSDA 
+ 
GTT 
+ 
C. glabrata 
19% (38) Round, oval, 
big, yeast like 
cells, 
budding cells 
White, Pink, 
Purple 
No 
pseudohyphae, 
cells small, 
terminal budding 
+ 
7% (14) 
Cparapsilo 
sis 
Round, oval, 
big, yeast like 
cells, 
budding cells 
White, Pale, Pink 
Blastospores 
along curved 
pseudohyphae; 
giant mycelial 
cells 
+ 
5% (10) 
C. tropicalis 
Round, oval, 
big, yeast like 
cells, 
budding cells 
Black blue to 
blue gray with 
dark halo in 
centre 
Blastospores any 
where along 
pseudohyphae 
+ 
C. krusei 
3% 
(6) 
Round, oval, 
big, yeast like 
cells, 
budding cells 
Pale, Pink, 
Purple 
Pseudohyphae 
with "cross-
sticks" 
blastospores 
1.5% (3) 
C.kyfer 
Round, oval, 
big, yeast like 
cells, 
budding cells 
Large, rough, 
pink to 
levenvendor, 
often with 
darkened centers 
Elongated 
blastospores 
resembling "logs 
in a stream along 
pseudohyphae" 
No.are given in parenthesis 
Total no. of patients = 175 
Total no. of Candida isolates are 200 
+ = positive 
- = negative 
GTT =Germ Tube Test 
+ 
C. albicans C. tropicalis 
C. krusic C. glabrata 
C.parapsilosis C. kyfer 
C. guilliermondi 
Fig. 2 Morphology of various Candida species on chrome Candida agar and Com meal 
agar, (left chromeagar, right com meal agar at lOOX, at 25°C and 72 hrs. incubation 
(A) GTT slide of C. albicans at lOOX 
(B) Slide of Candida on KOH at lOOX 
Fig.2.2 Morphology of various Candida species on GTT slide and KOH slides at 100 X. 
Table 5: Biochemical characterization of isolated specimen 
5.1 Sugar Fermentation 
Candida species isolated 
C. albicans 
Cglabrata 
C. parapsilosis 
C. tropicalls. 
C. krusei 
C. kyfer 
% of total 
isolates 
64.5% (29) 
19% 
(38) 
7% 
(14) 
5% 
(10) 
3% 
(6) 
1.5% 
(3) 
Dex. 
AG 
AG 
AG 
AG 
AG 
AG 
Malt. 
AG 
-
-
AG 
-
AG 
Sue. 
A 
-
-
AG 
-
AG 
Lact. 
-
-
-
-
-
-
Galact. 
AG 
-
AG 
AG 
-
AG 
No.are given in parenthesis 
Total no. of patients = 175 
Total no. of Candida isolates are 200 
AG = Acid + Gas (+ve) 
A = Acid formation (+ve) 
= No Acid No Gas (-ve) 
Dex ^Dextrose 
Malt = Maltose 
Lact = Lactose 
Sue = Sucrose 
Galact ^Galactose 
5.2 Sugar Assimilation 
Candida 
species isolated 
C. albicans 
C. glabrata 
C. parapsilosis 
C. (ropicalis 
C. krusei 
C. kyfer 
64.5% 
(129) 
19% 
(38) 
7% (14) 
5% (10) 
3% 
(6) 
1.5% (3) 
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No.are given in parenthesis 
Total no. of patients = 175 
Total no. of Candida isolates are 200 
+ = Positive 
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Fig.3: Distribution pattern of different Candida species isolated from gynecology OPD 
Table 6: Distribution of Candida species in different cultures with 
respect to age group of patients attending gynecology OPD 
No. of patients of different age group with Candida infections 
Total No. of Candida 
isolates 
Culture having single 
species" 
C. albicans (129) 
C. glabrata (38) 
C. parapsilosis (14) 
C .tropicalis (\0) 
C. krusei (6) 
C. kyfer (3) 
Culture having two 
species 
C. albicans, 
C. glabrata 
C. albicans, 
C. parapsilosis 
C. albicans, 
C. kyfer 
C. tropicalis 
C. parapsilosis 
C. albicans, 
C. tropicalis 
C. albicans, 
C. krusei 
C. glabrata, 
C. tropicalis 
Culture having three 
species 
C. albicans, 
C. glabrata & 
C. tropicalis 
C. albicans, 
C. parapsilosis & 
C. glabrata 
Total 
cultures 
155 
113 
24 
9 
2 
5 
2.. 
15 
- ) J 
1 
1 
2 
5 
1 
2.. 
5 
o J 
2 
15-24 
yrs 
45 
28 
10 
4 
1 
1 
1 
9 
2 
1 
1 
1 
2 
1 
1 
2 
1 
1 
25-34 
yrs 
32 
17 
8 
2 
1 
3 
1 
3 
1 
-
-
1 
-
1 
2 
1 
1 
35-44 
yrs 
32 
25 
4 
2 
-
1 
-
2 
-
-
1 
1 
-
-
1 
1 
45-54 
yrs 
34 
32 
1 
1 
-
-
-
1 
-
-
-
-
1 
-
-
0 
55-64 
yrs 
6 
4 
1 
-
-
-
-
0 
-
-
-
-
-
-
-
0 
65-74 
yrs 
6 
6 
-
-
-
-
-
0 
-
-
-
-
-
-
-
0 
a == No. of each species is given in parenthesis 
Total no. of patients is 175 
Total no. of Candida isolates 200 
* =Age at first visit to gynecology OPD 
Table 7: Distribution of Candida species in single culture and mix 
cultures 
Culture with 
Single species 
Culture with 
Mixtures of 
Two species 
Culture with 
Mixtures of 
three species Total 
.Candida 
species isolated 
C. albicans 
C. glabrata 
C .parapsilosis 
C. tropicalis 
C. krusei 
C. kyfer 
No of 
Candida 
species 
isolated 
113 
24 
9 
2 
5 
2 
%of 
total 
no.of 
each 
Candida 
species 
from all 
cultures 
87.60 
63.16' 
64.29 
20 
83.33 
66.67 
No of 
Candida 
species 
isolated 
11 
9 
3 
5 
1 
1 
%of 
total 
no.of 
each 
Candida 
species 
from all 
cultures 
8.5 
23.68 
21.43 
50 
16.67 
33.33 
No of 
Candida 
species 
isolated 
5 
5 
2 
3 
0 
0 
%of 
total 
jio.of 
each 
Candida 
species 
from all 
cultures 
3.88 
13.15 
14.29 
30 
0 
0 
Total no. 
of each 
Candida 
species 
from all 
cultures 
129 
38 
14 
10 
6 
3 
% of 
total 
isolates 
from all 
cultures 
64.25 
19 
7 
5 
^ J 
1.5 
Total no. of patients is 175 
Total Candida isolates from all cultures are 200 
Table 8: Clinical profile and age distribution of 175 patients attending 
gynecology OPD 
No. of patients of different age* group with Candida infections 
Clinical states 
of patients 
Urinary tract 
infection 
Chronic 
sinusitis 
Acne 
Vulvar 
contactdermitis 
Vulvar 
vestibulitis 
VIN 
Lichen 
schlerosis 
Diabetes 
CINl 
Urinary 
incontinence 
Hormone 
replacement 
therapy 
%of 
total 
175 
30% 
(60) 
4% 
(8) 
3% 
(6) 
57% 
(114) 
20% 
(40) 
24% 
(48) 
10% 
(20) 
12.5% 
(25) 
2.5% 
(5) 
1.5% 
(3) 
10% 
(20) 
15-24 
yrs 
10 
5 
5 
24 
20 
8 
8 
6 
-
-
25-34 
yrs 
12 
1 
1 
20 
4 
5 
4 
5 
-
-
35-44 
yrs 
7 
1 
-
26 
8 
15 
5 
5 
1 
1 
45-54 
yrs 
25 
1 ., 
-
29 
8 
12 
3 
6 
3 
1 
10 
55-64 
yrs 
3 
-
-
9 
-
6 
-
2 
1 
1 
8 
65-74 
yrs 
3 
-
-
6 
-
2 
-
1 
-
-
2 
* =Age at first visit to gynecology OPD 
Total no. of patients = 175 
a = Total no. of Candida isolates 200 
No. are given in parenthesis 
CIN 1 =Cervical Intraepithelial Neoplasia 1 
VIN =Vulvar Intraepithelial Neoplasia 
Table 9: Occurrence of Candida species in vagina and cervical 
Candida species 
isolated 
C. albicans 
C. glabrata 
C. parapsilosis 
C. tropicalis 
C. krusei 
C. kyfer 
Total isolated 
species of 
Candida 
Candida isolates* 
129(64.5%) 
38 (19%) 
14(7%) 
10(5%) 
6 (3%) 
3(1.5%) 
200 
No. of Candida 
isolates from 
cervical 
40(31%) 
10(26.32%) 
5 (35.71%) 
3(31%) 
1 (16.67%) 
1 (33.33%) 
60 (30%) 
No. of Candida 
isolates from 
vagina 
89 (68.99%) 
28 (73.68%) 
9 (64.29%) 
7 (70%) 
5 (83.33%) 
2 (66.67%) 
140 (70%) 
Total no. of patients = 175 
a = Total no. of Candida isolates 200 
% are given in parenthesis 
Table 10: Distribution of Candida species in pregnant / non-pregnant 
women 
Candida species | 
isolated 
C. albicans 
C. glabrata 
C .parapsilosis 
C. tropicalis 
C. krusei 
C. kyfer 
Total isolated 
species of 
Candida 
No. of Candida 
isolates^ 
129(64.5%) 
38(19%) 
14 (7%) 
10(5%) 
6 (3%) 
3(1.5%) 
200 
No. of Candida 
species isolated 
from pregnant 
women 
72(55.81%) 
21 (55.26%) 
9 (64.29%) 
4 (40%) 
3 (50%) 
1 (33.33%) 
110(55%) 
No. of Candida 
species isolated 
from non-pregnant 
women 
57(44.19%) 
17(44.74%) 
5(35.71%) 
6 (60%) 
3 (50%) 
2 (66.67%) 
90 (45%) 
Total no. of patients = 175 
a = Total no. of Candida isolates 200 
% are given in parenthesis 
Table 11: % Resistance of Candida species against different antifungals 
a = Total no. of Candida isolates 200 
Total no. of patients is 175 
No. are given in parenthesis 
It = Itraconazole (10 meg) 
Kt = Ketoconazole (10 meg) 
Ns ^Nystatin (100 meg) (10 meg) 
Cc= Clotrimazole (10 meg) 
Fu =Fluconazole (10 meg) 
Ap = Amphotericin-B (100 meg) 
Candida 
speeies 
isolated 
C. albicans 
C. glabrata 
C.parapsilosis 
C. tropicalis 
C. krusei 
C. kyfer 
Total % 
resistance of 
each 
antifungal 
drug 
% Resistant of eac 
% 
occurrence 
of each 
Candida 
species^ 
64.25% 
(129) 
19% 
(38) 
7% 
(14) 
5% 
(10) 
3% 
(6) 
1.5% 
(3) 
% 
Resistance 
of each 
species 
against 
It 
62.01% 
(80) 
78.95% 
(30) 
50% 
(7) 
50% 
(5) 
50% 
(3) 
33.33% 
(1) 
63% 
(126/200) 
1 antifungal 
% 
Resistance 
of each 
species 
against 
Kt 
46.51% 
(60) 
52.63% 
(20) 
42.86% 
(6) 
30% 
(3) 
33.33% 
(2) 
33.33% 
(1) 
46% 
(92/200) 
drus asainst each species 
% 
Resistance 
ofeach 
species 
against 
Ns 
23.26% 
(30) 
2.33% 
(3) 
0% 
(0) 
10% 
(1) 
0% 
(0) 
0% 
(0) 
17% 
(34/200) 
% 
Resistance 
ofeach 
speeies 
against 
Cc 
23.26% 
(30) 
2.33% 
(3) 
0% 
(0) 
0% 
(0) 
0% 
(0) 
0% 
(0) 
16.5% 
(33/200) 
% 
Resistance 
of each 
species 
against 
Fu 
4.56 % 
(6) 
7.89 % 
(3) 
• 0 % 
(0) 
20% 
(2) 
66.67 % 
(4) 
0% 
(0) 
7.5% 
(15/200) 
% 
Resistance 
of each 
species 
against 
Ap 
3.88% 
(5) 
15.79% 
(6) 
21.43% 
(3) 
10% 
(1) 
66.67% 
(1) 
0% 
(0) 
8% 
(16/200) 
60 
50 
40 
« o c 
5 
0) 
O 
a. 
20 
10 
Kt Cc 
Antifungals 
Ap 
Fig.4: Comparison of total resistant of different antifungals against different Candida 
species isolated from gynecology OPD. 
3.4 Discussion: 
In this study, C. albicans was the most prevalent species associated with 
vaginal candidiasis (64.25 %). Which is similar to results in other European (54-66 
%) and Americans (45-55 %) countries (Pfaller et al 2001, Matteo et al 2006, 
Luzzati et al 2000). Candida glabrata was the second most frequently isolated yeast 
(25.7%), consistent with the results of other data (Linhares et al 2001, Cemicka et al 
2006). This species is represented in 16.3% and 38.1% of the cases in the studies of 
Bauters et al. (Bauters et al 2002) and Verghese et al. (Verghese et al 2001), 
respectively. 
The overall percentage of non-albicans vaginitis (35.5 %) is higher than in 
two previously reported data (Holland et al 2003, Cheng et al 2006). Spinillo et al. 
reported 17% of 209 isolates from symptomatic patients referred to an Italian 
vulvovaginitis clinic were non-albicans species in 1995 (Cheng et al 2006). An 
Australian study found vulvovaginal yeast carriage among 21% of 5, 802 women, 
receiving a pelvic exam in a primary care setting; non-albicans species were isolated 
in only 11% of the positive cultures (Holland et al 2003). This difference likely 
reflects a bias towards more complicated patients in the current study who are 
symptomatic and had prior episodes before being referred to a gynecology OPD. 
Non- albicans species are reported as lower rate in previous study (Ozacan et al 
2006, Kuriyama et al 2005) copared to the current study. 
The subset of isolates from patients with multiple positive cultures during the 
study period included a higher percentage of non-albicans species (64.44 %) than the 
isolates from patients with only one positive culture (27.09 % non-albicans). The 
marked difference in species distribution between these two groups may be the 
result of a higher level of antifungal exposure among patients with multiple positive 
cultures providing selective pressure for non-albicans species that are more likely to 
be azole resistant. An alternative explanation is that patients who develop 
vulvovaginitis from a non-albicans species are more likely to fail therapy and have 
multiple positive cultures. 
The prevalence of C albicans noted among the subset of patients with 
multiple positive cultures in the current study (38.55 %) was similar to the 
prevalence of C. albicans reported by Candida bloodstream infection surveillance 
studies (52 to 56%) (Pfalle et al 1999). The prevalence of C glabrata (17.78 %) 
among patients with multiple positive vaginal cultures was similar to that reported 
among bloodstream isolates (8 to 18%) (Pfalle et al 2000). 
The distribution of Candida species in patients of different age group is 
similar to those of previous studies based on similar groups of host and body sites 
(Inping et al 2004;Bedini et al 2006). The percentage occurrence'of different 
medical conditions among the patients is within the range of previous studies 
(Sandra et al 2005). 
In the present study, statistically highly significant difference in incidence of 
vaginal candidiasis was observed between pregnant and non-pregnant women (Table 
2). Vaginal candidiasis is more common and difficult to eradicate during pregnancy 
(Marcia et al 2004, Chander 2002). This is probably due to high level of 
reproductive hormones during pregnancy, which provides an excellent carbon 
source for growth of Candida High incidence of vaginal candidiasis observed in 
patients using oral contraceptives, is similar to the earlier coworkers (Marcia et al 
2004, Chander 2002). Significant influence increasing use of antibiotics in vaginal 
candidiasis was observed in the present study. Antibiotics are knowTi to destroy the 
normal protective vaginal flora and help in colonization with Candida. C. tropicalis 
and C. kyfer are more frequently isolated from non- pregnant women. 
According to in vitro antifungal susceptibility testing, 8 % and 7.5 % of isolates are 
considered resistant to amphotericin B and fluconazole, respectively. The difference 
in rate of resistance between fluconazole and amphotericin B is due to different 
mechanisms of antifungal activity (Cemicka et al 2006, Pfaller et al 2002), 
frequency of use of different molecular mechanisms of drug resistance (Morgan, 
2005, Cemicka et al 2006). 
Fungal infections caused by non-albicans Candida species have been 
increasing dramatically (Bedini et al 2006, Slavin et al 1995, Kuriyama et al 2005). 
C. h-usei and C glabrata have been considered intrinsically more resistant to 
fluconazole (Bedini et al 2006, Tortorano et al 2004). In this study, no C krusei 
isolate was susceptible to fluconazole, but C.glabrata was less resistant to 
fluconazole than in other studies (10 % vs 13% or 45.4%) (St. Germain et al 2001, 
Safdar et al 2001). Overall, non-albicans Candida species have higher rates of 
resistance to fluconazole than did C albicans. 
The increasing rate of fluconazole resistance in C. tropicalis (19 %) is 
important because C. tropicalis is one of the most commonly found non-albicans 
Candida species (Ozcan et al 2006, Holland et al 2003). C. tropicalis develops drug 
resistance in the presence of 
fluconazole much more rapidly than does C. albicans (Barchiesi et al 2000, 
Antunes et al 2004). These findings may explain why C. tropicalis (19 %) had a higher 
rate of resistance to fluconazole than C albicans (5 %) and C glabrata (10 %). 
The use of azole antifungals, particularly fluconazole, may also lead to a 
pathogen shift with increased incidence of the inherently resistant Candida species 
such as C glabrata and C krusei (Antunes et al 2004, Ostrosky et al 2003). The 
widespread use of azoles has led to an increase in the prevalence of fluconazole-
resistance among non-albicans species, especially C. glabrata (Sobel 1998, 
Vazquez et al 1999, Nguyen et al 1996, Cross et al 2000, Alexander et al 2005, 
Morgan, 2005). 
C. albicans exhibiting high-level resistance to fluconazole may express 
several mechanisms of resistance (Perea et al 2001, Morgan, 2005). Those isolates 
of C. albicans with a phenotype of high-level resistance to both fluconazole and 
itraconazole may overexpress both MDR and CDR efflux pumps with or without 
ERG 16 mutations or overexpression, whereas strains with high-level resistance to 
fluconazole and susceptibility to itraconazole may over express the MDR pump but 
not the CDR pump (Perea et al 2001, Morgan, 2005). 
Resistance of different Candida species to other antifungals (Ketoconazole, 
Nystatin, Clotrimazole, Amphotericin-B) are with in the range of previous studies 
(Sandra et al 2005). Thus our study and previous studies (Sandra et al 2005, Antunes 
et al 2004) suggests Fluconazole and Amphotericin B as the most effective 
antifungal drugs in patients attending gynecology OPD. 
Chapter-4 
Isolation. Characterization 
& 
Drug Resistance Pattern of 
Candida Species Isolated 
from NICU. 
4.1 Introduction: 
Candida species is important nosocomial pathogens in the newborn population, 
particularly among the preterm. Colonization of the neonatal skin and 
gastrointestinal tract is the first step in the pathogenesis of invasive Candidiasis 
(Pittet at al 19941) C. albicans is the most commonly isolated species in colonized 
or infected infants. However, in the past decade infection and colonization with 
other species of Candida has risen dramatically and high rates of yeast carriage in 
neonates, especially preterm has been reported by many workers (Sharp at al 1992; 
Singh at al 1999; Baley at al 1986) This has been attributed tojthe advancement in 
technology, life support systems, relative immunodeficiencies in the preterm, high 
prevalence of hand carriage of Candida in health care workers,(Phelps at al 1986; 
Bumie at al 1985) ability of Candida to survive on environmental surfaces (Pfaller 
1995) and colonization of maternal vagina (Seeling 1996) Colonization of the infant 
occurs early in life and this is affected by a variety of common practices in the 
neonatal intensive care unit (NICU). Presently, there is a paucity of information on 
fungal colonization in preterm infants. Keeping the above facts in view this study 
had been undertaken in preterm admitted in NICU of a rural tertiary care hospital to 
find out the rate, risk factors and source of colonization by various species of 
Candida. Colonization with Candida species is an important risk factor for systemic 
infection in very low birth weight (VLBW; <1500 g) and extremely low birth weight 
(ELBW, <1000 g) infants. ELBW infants are at a higher risk than VLBW infants for 
fungal sepsis and its associated mortality, but few studies have examined fungal 
colonization exclusively in ELBW infants (Kaufman et al 2006). Invasive Candia 
infections have become the third most common cause of late-onset infection among 
very low birth weight infants in most neonatal intensive care units. Significant risk 
factors include birth weight less than 1000 g, exposure to more than two antibiotics, 
third generation cephalosporin exposure, parenteral nutrition including lipid 
emulsion, central venous catheter, and abdominal surgery. The majority of neonatal 
Candida infections are caused by C. albicans and C. parapsilosis, although other 
nonalbicans species are being reported more frequently (Chapman 2007). 
4.2 Material and methods: 
The present study was conducted for a period of 1 year 4 months from Nov. 
2005 to March 2007 on samples isolated from Jawaharlal Nehru Medical College 
(JNMC) & Hospit 
Lactophenol Cottop Blue (LPCB) , KOH & Gram staining slides were made 
of all the isolates to differentiate between yeast and bacteria.All the isolates having 
yeast like cells were plated on HiChrome Candida Differential Agar (Hi-Media 
chemicals, India), to ensure the detection of mix infections.Culture were incubated 
at 37 °C for 48 hrs.AU the Calbicans show green colony on HiChrome Candida 
Differential Agar and they were further confirmed by the GTT (Germ Tube Test). 
GTT is posative for Calbicans only. For further morphological identification rest of 
the cltures were plated on Com Meal Agar (Hi-Media chemicals, India). Furthur 
confirmation was done by sugar assimilation and sugar fermentation tests. 
All the 150 positive Candida isolates were tested on Sebaraud Dextrose Agar 
for their sensitivity against six antifungals namely Amphotericin-B, Nystatin, 
Clotrimazole, Itraconazole, Fluconazole and Ketoconazole. 
5 ml of sterilized SDA broth were poured into autoclaved, plugged test tubes 
and each tube inoculated with positive samples of Candida. The inoculated tubes are 
then kept in incubator at 37°C for 24 hours. Each inoculum is then spread over 
solidified SDA plates .Sterlized forceps were then used to apply antifungal discs and 
the sensitivity plates were incubated overnight at 37''C. The sensitivity was 
monitered by visualizing the zone of inhibition around the disc (Bauer et al 1996). 
4.3 Results: 
A total of 1825 samples were collected from NICU, JNMC, AMU Aligarh. 
Out of 1825 samples 500 samples were showing signs and symptoms of the disease. 
Out of these 500 samples only 138 samples were positive for Candida. From these 
138 posative samples 150 Candida isolates were obtained at, AMU and Feroz 
Specialist Hospital & Research Center (FSHRC), Aligarh. Out of 150 isolates 79 
(52.67 %) were C. albicans, C. tropicalis 27 (18 %), C. parapsilosis 6 (12.67 %), C. 
glabrata were 19 (10 %), C. krusie 10 (5 %), C. kyfer 3 (1.5 %) (Table 12, 13, 14). 
More comprihensive picture of % occurrence of each Candida species is shown in 
fig.3. 
Out of total 150isolates, 55 (36.67 %) were from blood, 28 % from urine, 12 
% from eye lid, 12.67 % from body surface, 6.67 % from umblical tip and 4 % from 
CSF (Cerebrospinal fluid). Predominantly isolated species from blood was C. 
albicans (41.81 %) followed by C. tropicalis (27.27 %). Predominantly isolated 
species from urine was C. albicans (50 %) followed by C. glabrata (23.80 %). 
Predominantly isolated species from eye lid was C. albicans (55.56 %) followed by 
C. krusie (16.67 %). Predominantly isolated species from body surface C. albicans 
(63.16 %) followed by C. tropicalis (15.79 %). Predominantly isolated species from 
umbilical tip was C. albicans (70 %) followed by C. tropicalis (20 %). C. albicans 
was the only species isolated from CSF (Cerebrospinal fluid) (table 15). 
Maximum C. albicans infection was found in CSF followed by umblical tip. 
Maximum C. tropicalis infection was found in blood (22.27 %) followed by 
umblical tip. (20 %). Maximum C. glabrata infection was found in urine (23.8 %) 
followed by blood (12.72 %). Maximum C. krusie and C. parapsilosis infection was 
found in urine (23.8 %) followed by blood (10.9 %). Maximum C. gluilliermondi 
infection was found in body surface (Table 15). 
Non-albicans species (58.18 %) was dominant over C. albicans (41.8 %) in 
blood isolates. Non-albicans species and C. albicans species are equally isolated 
from urine cultures. C. albicans species is dominated over the non-albicans species 
in eye lid, body surface, umblical tip, and CSF cultures. (Table 15). 
Total 150 Candida isolates were isolated from 138 neonates. Out of 150 
Candida isolates, 90 (60 %) were isolated from male neonates and 60 (40 %) were 
isolated from female neonates. In male and female neonates C. albicans was 
predominantly isolated followed by C. tropicalis (Table 16). 
The age of neonates at the time of sample collection vary from 5 days to 7 
days. The frequency of C. albicans was observed in neonates of age 5 days followed 
by 6 days and 7 days (70 %, 53.33 %, and 45.45 % respectively). Maximum 
Candida infections were observed in neonates of age of 7 days followed by 6 days 
and 5 days (73.33 %, 20 % and 6.67 % respectively). The % of infection due to non-
albicans species increases as the age of neonates increases (table 16). 
The weight of the neonates at the time of sample collection ranges from 400 
gm to 4000gm. Maximum (73.33 %) Candida infection was observed in neonates of 
weight group 400 gm-lOOOgm and least was observed in 3401-4000gm (2 %). C. 
albicans was predominantly isolated from neonates of weight group 400-lOOOgm. 
(50.90 %) and least in 3401-4000gm. (33.33 %). Prevalence of non-albicm species 
increases as weight increases. The prevalence of Candida infection was higher 
(96.67 %) in neonates having vaginal birth as compared to non-vaginal birth. 
The gestational age varies from 24 weeks to 46 weeks. The neonates of 
gestational age 24 weeks to 35 weeks were preterm, 36-41 weeks term and 42-46 
weeks post term. The prevalence of Candida infection was maximum in preterm of 
gestational age 24-29 weeks (53.33 %) followed by 30-35 weeks (26.67 %) and least 
Candida infection was observed in term neonates and posterm neonates (10 % each). 
Frequency of C. albicans was maximum in 24-29 weeks gestational age neonates 
(56.25 %) followed by 30-35 (26.67 %) and least in 30-46 weeks gestational age. % 
of non-albicans increases as the gestational age increases (table 16). 
Out of 138 neonates, 128 (92.75 %) neonates were having infection of single 
species of Candida, 8 (5.78 %) have infection of two species and 2 (1.45 %) have 
infection of three species (table 17). Total 128 Candida isolates were isolated from 
culture having single species Out of 128 Candida isolates. 73 (57.03 %) were C. 
albicans. The % of non-albicans in cultures having single species was 42.97 %. Out 
of 8 patients having infection of two species 2 were having infection of C. albicans 
and C. glabrata, 2 C. albicans and C. parapsilosis, 2 C. tropicalis and C. 
parapsilosis,\ C. tropicalis and C. albicans and 1 C. tropicalis and C. glabrata. The 
% of C. albicans in cultures having two species was 31.25 %; it is quite lower than 
the % (57.03 %) of C. albicans in cultures having single species The % of non-
albicam in cultures having two species was 68.75 %; it is quite higher than the % 
(42.79 %)of non-albicans species in cultures having single species Out 2 patients 
having infection of three species 1 was having infection of C. albicans and C. 
glabrata and C. tropicalis and 1 was having C. krusie and C. parapsilosis and C. 
tropicalis. Total 6 Candida isolates were isolated from these two patients having 
infection of three species Out of 6 Candida isolates 1 (16.67 %) were C. albicans. 
The % of C. albicans in culture having three species was nearly half the of % C. 
albicans in culture having two species (31.25 %) and the % of C. albicans in culture 
having three species was nearly one third of the of % C. albicans in culture having 
two species (57.03 %). The % of non-albicans in culture having three species was 
(83.33 %). It was higher than the % of non-albicans in cultures having two species 
(68.75 %) and the % of non-albicans in cultures having single species (42.97 %) 
(Table 17). 
Susceptibility test for each species are shown in (table 18). Susceptibility 
testing was performed using disc diffusion method. Our results revealed that 52.67 
% isolates were resistant against Itraconazole, followed by Ketoconazole (34 %), 
Fluconazole (18.67 %), Nystatin (13.33 %), Clotrimazole (10.67 %) and 
Amphotericin-B (5.70 %). More comprehensive picture is shown in (fig. 19). 
Itraconazole resistance was observed maximum in C. tropicalis (66.67 %), followed 
by C. krusie (53.33 %), C. glabrata{52.63 %), C. albicans (50.63 %), C. 
parapsilosis (33.33 %) and least in C. ghiilliermondi (25 %). Ketoconazole 
resistance was observed maximum in C. albicans (44.30 %), followed by C. 
parapsilosis (33.33 %), C glabrata (26.31 %), C. krusie (26.67 %), C. gluilliermondi 
(25 %) and least C. tropicalis (14.81 %). Nystatin resistance was observed 
maximum in C. albicans (20.25 %) followed by C. parapsilosis (16.67 %) and no 
resistance was observed in C. gluilliermondi. Maximum Clotrimazole resistance was 
observed maximum in C. albicans (18.99 %) followed by C. tropicalis {}.lQi %). No 
resistance was found in C. glabrata, C. krusie, C. parapsilosis and C. gluilliermondi. 
(Table 18) 
Maximum Fluconazole resistance was observed in C. krusei (44.67 %) 
followed by C. albicans ill.11 %), C. glabrata (15.78 %), C. tropicalis (14.81 %). 
No resistance against Fluconazole was observed in, C. parapsilosis and C. 
gluilliermondi. Maximum Amphotericin-B resistant was observed in C .krusie 
(16.67 %), followed by C. tropicalis (15.79 %), C. albicans (1.27 %), and no 
resistance against Amphotericin-B was observed in C. glabrata, C. parapsilosis and 
C. gluilliermondi. {Tah\e \S). 
Out of 150 Candida isolates, 40 Candida isolates were from neonates which 
were studied for their mode of transmission from mother's vaginal mucosa to her 
neonates (table 19). Out of 40 samples, 20 were from blood, 13 from urine and 7 
from skin of neonates. The samples were also taken from their corresponding 
mother's vaginal mucosa. Of 40 neonates, 35 had vaginal delivery and remaining 
were through non-vaginal delivery It was found that among 40 neonates; 9 (22.5 %) 
neonates showing to have same species as isolated from mother's vaginal mucosa. 
Among these species having concordance, only 7 were found to have same 
sensitivity pattern (77.78 %). The over all concordance was 7/40 (17.5 %). No 
concordance was found in neonates having non-vaginal delivery. Maximum 
concordance of Candida species was found in urine cultures (38^46 %) followed by 
skin cultures (28.57 %) and blood (20 %). Maximum susceptibility concordance was 
observed in urine cultures.(23.67 %) followed by blood (75 %) and skin (14.29 %) 
(Table 19). 
Table 12: Characterization of Candida species based on the morphology. 
Candida 
species 
isolated 
C. albicans 
C. tropicalis 
C. 
parapsilosis 
C. glabrata 
C. krusei 
C. guilliermon 
S CO 
o o , 
52.67 
(79) 
18(27) 
12.67 (6) 
10(19) 
4 
(15) 
2.67 (4) 
Morphology on 
1KOH slide 
Round, oval, 
big, yeast like 
cells, budding 
cells 
Round, oval, 
big, yeast like 
cells, budding 
cells 
Round, oval, 
big, yeast like 
cells, budding 
cells 
Round, oval, 
big, yeast like 
cells, budding 
cells 
Round, oval, 
big, yeast like 
cells, budding 
cells 
Round, oval, 
big, yeast like 
cells, budding 
cells 
Morphology on 
Hi- chromo 
Candida agar 
Green 
Black blue to 
blue gray with 
dark halo in 
centre 
White, Pale, 
Pink 
White, Pink, 
Purple 
Pale, Pink, 
Purple 
Large, rough, 
pink to 
levenvendor, 
often with 
darkened 
centers 
Micro scopic 
morphology on 
CMA at 37°C 
Pseudohyphae 
with terminal 
chlamydospores; 
clusters of 
blastospores at 
septa 
Blastospores 
anywhere along 
pseudohyphae 
Blastospores 
along curved 
pseudohyphae; 
giant mycelial 
cells 
No 
pseudohyphae, 
cells small, 
terminal budding 
Pseudohyphae 
with "cross- • 
sticks" 
blastospores 
Fairly short ,fme 
pseudohyphae, 
clusters of 
blastospores at 
septa 
Growth 
on 37°C 
onSDA 
+ 
+ 
+ 
+ 
+ 
+ 
GTT 
+ 
-
-
-
-
No.are given in parenthesis 
Total no. of Candida isolates are 150 
+ = positive 
- = negative 
GTT =Germ Tube Test 
CMA = Com Meal Agar 
Table 13: Biochemical characterization of isolated specimen 
Sugar Fermentation 
Candida species 
isolated 
C. albicans 
C. tropicalis 
C. glabrata 
C. krusei 
C. parapsilosis 
C. gluilliermondi 
% of total 
isolates 
52.67 (79) 
18(27) 
12.67 (6) 
10(19) 
4(15) 
2.67 (4) 
Dex. 
AG 
AG 
AG 
AG 
AG 
AG 
Malt. 
AG 
AG 
-
-
-
-
Sue. 
A 
AG 
-
-
-
AG 
Lact. 
-
-
-
-
-
Galact. 
AG 
AG 
-
-
AG 
AG 
No.are given in parenthesis 
Total no. of patients is 138 
Total no. of Candida isolates are 150 
AG = Acid + Gas (+ ive) 
A = Acid formation (+ ive) 
= No Acid No Gas (- ive) 
Dex ^Dextrose 
Malt = Maltose 
Lact = Lactose 
Sue = Sucrose 
Galact ^Galactose 
Table 14: Sugar Assimilation 
Candida species 
isolated 
C. albicans 
C. tropicalis 
C. glabrata 
C. krusei 
C. parapsilosis 
C. gluilliermondi 
CQ CO 
O t i 
+-• c3 
y . . 1 — » 
o o 
52.67 (79) 
18 (27) 
12.67 (6) 
10(19) 
4 
(15) 
2.67 (4) 
t/i 
O 
(U 
+ 
+ 
+ 
+ 
+ 
+ 
o 
CO 
+ 
+ 
+ 
+ 
CO 
O 
o 
3 
00 
+ 
+ 
+ 
+ 
CO 
O 
o 
03 
-
-
-
-
CO 
O 
• • - • o 
03 
+ 
+ 
+ 
+ 
CO 
O 
-
-
-
+ 
CO 
O 
_o 
O 
-
+ 
-
+ 
'co 
O 
C 
1—H 
-
-
-
J 
1) 
CO 
X 
+ 
+ 
+ 
+ 
CO 
O 
C 
-
-
-
+ 
CO 
u 
+ 
+ 
+ 
+ 
o 
-•-» 
3 
Q 
-
-
-
+ 
o 
-
-
-
-
-
-
No.are given in parenthesis 
Total no. of patients is 138 
Total no. of Candida isolates are 150 
+ = Positive 
- =Negative 
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Fig.5: Distribution pattern of different Candida species isolated from NICU. 
Table 15: Distribution of Candida species at different sites 
Site of 
isolation of 
organism 
Blood 
Urine 
Eye lid 
Body surface 
Umbilical tip 
CSF* 
Total no. of 
Candida 
isolates 
1 
Total 
positive 
isolate 
55 
42 
18 
19 
10 
6 
150 
u 
23 
21 
10 
12 
7 
6 
79 
(52.67%) 
.2 
"a 
15 
5 
2 
3 
2 
-
27 
(18.0%) 
O 
1 
10 
1 
1 
-
-
19 
(12.67%) 
"S 
cJ 
6 
4 
3 
1 
1 
-
15 
(10.0%) 
to 
a" 
U 
2 
1 
2 
1 
-
-
6 
(4.0%) 
c 
o 
S 
•Si 
S 
cJ 
2 
1 
-
1 
-
-
4 
(2.67%) 
%.are given in parenth 
Total no. of Candida isolates are 150 
CSF = * Cerebrospinal fluid 
Table 16: Clinical profile of Candida species Among the neonates with respect 
to their sex, age, weight, gestational age & nature of birth 
Medical history 
Sex 
Male 
Female 
Age* (days) 
5 
6 
7 
Weight** (g) 
400-1000 
1001-1600 
1601-2200 
2201-2800 
2801-3400 
3401-4000 
Vaginal Birth 
Non-vaginal Birth 
Gestational age 
24-29 Preterm 
30-35 Preterm 
36-41 term 
42-46 post term 
Total no. of isolates 
of each species 
Tota 
Ino. 
150 
90 
60 
10 
30 
110 
110 
20 
8 
5 
4 
3 
145 
5 
80 
40 
15 
15 
u 
45 
34 
7 
16 
.. 50 
56 
9 
3 
2 
2 
1 
72 
2 
45 
18 
.. 6 
5 
79 
(52.67%) 
'I 
U 
15 
12 
4 
7 
20 
18 
6 
2 
1 
1 
1 
26 
1 
15 
5 
5 
4 
27 
(18.0%) 
53 
?3 
o 
13 
6 
2 
3 
18 
15 
2 
2 
2 
1 
1 
18 
1 
10 
7 
1 
2 
19 
(12.67%) 
•3 s 
8 
7 
1 
2 
14 
13 
2 
0 
0 
0 
0 
15 
0 
5 
8 
1 
2 
15 
(10.0%) 
1 
6 
0 
0 
2 
4 
• 4 
1 
1 
0 
0 
0 
5 
1 
3 
2 
1 
2 
6 
(4.0%) 
o 
S 
•Si 
a 
bo 
U 
3 
1 
0 
0 
4 
4 
0 
0 
0 
0 
0 
4 
0 
2 
1 
0 
0 
4 
(2.67%) 
Total no. of patients is 138 
Total no. of Candida isolates are 150 
*= age at the time of sample collection 
**= Weight at the time of sample collection 
Table 17: Candida species distribution in different cultures 
Distribution of Candida species 
Culture having single species 
C. albicans 
C. tropical is 
C. glabrata 
C. krusei 
C .parapsilosis 
C. gluilliermondi 
Culture having two species 
C. albicans ,C. glabrata 
C. albicans ,C.parapsilosis 
Ctropicalis ,C. parapsilosis 
C. albicans,Ctropicalis 
C. glabrata,Ctropicalis 
Culture having three species 
C. albicans ,C glabrata & Ctropicalis 
Ctropicalis ,C parapsilosis & C. h-usei 
No. (%) of total 
culture 
(128)92.75 
73 
21 
15 
14 
1 
4 
(8) 5.78 
2 
2 
2 
1 
1 
(2)1.45 
1 
1 
Total Candida 
isolates from 
culture 
128 
16 
6 
No.are given in parenthesis 
Total no. of patients is 138 
Total no. of Candida isolates are 150 
Table 18: % Resistance of Candida species against different antifungals 
Total no. of 
Candida species 
C. albicans 
C. tropical is 
C. gla brat a 
C. krusei 
C .parapsilosis 
C. gluilliermondi 
Total % resistant 
of each 
antifungal drug 
o 
eu 
o « 
c o 
o 
o 
o 
52.67 
(79) 
18.0 
(27) 
12.67 
(19) 
10 
(15) 
4 
(6) 
2.67 
(4) 
150 
50.63 
(40) 
66.67 
(18) 
52.63 
(10) 
53.33 
(8) 
33.33 
(2) 
25.0 
(1) 
52.67% 
(79/150) 
J3 o 
1 s^ 
.2 '3 
44.30 
(35) 
14.81 
(4) 
26.31 
(5) 
(4) 
33.33 
(2) 
25.0 
0) 
34.0 % 
(51/150) 
X! 
o 
ctJ ^ 
^ G 
O Cd 6« 
«i a, 
20.25 
(16) 
3.70 
(1) 
5.26 
(1) 
6.67 
(1) 
16.67 
(1) 
0 
(0) 
13.33 % 
(20/150) 
o 
U 00 
o «J 3 
.22 'o 
CO (U 
« a, 
17.72 
(14) 
14.81 
(4) 
15.78 
(3) 
46.67 
(7) 
0 
(0) 
0 
(0) 
18.67% 
(28/150) 
X ! 
< « C 
(L> 00 
O CO CU 
.2 'o 
1.27 
(1) 
3.70 
(1) 
0 
(0) 
16.67 
(1) 
0 
(0) 
0 
(0) 
5.70 % 
(3/150) 
° -a 
u oo 
O «J W 
1 § 3 ^ 
.2 'o 
<u a. 
18.99 
(15) 
3.70 
(1) 
0 
(0) 
0 
(0) 
0 
(0) 
0 
(0) 
10.67% 
(16/150) 
Total no. of patients is 138 
a = Total no. of Candida isolates 150 
No. are given in parenthesis 
It = Itraconazole (10 meg) 
Kt = Ketoconazole (10 meg) 
Ns ^Nystatin (100 meg) (10 meg) 
Cc= Clotrimazole (10 meg) 
Fu =Fluconazole (10 meg) 
Ap = Amphotericin-B (100 meg) 
Kt Cc 
Antifungals 
Ap 
Fig.6: Comparison of total resistant of different antifungal against different Candida 
species isolated from NICU 
Table 19: Transmission of Candida species from mother to neonates 
Neonates 1 
1 
2 
3 
4 
5 
. 6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
34 
35 
36 
37 
38 
39 
40 
Site of 
Specimen 
Blood 
»9 
? ? 
Jt 
•>• 
• ' -
•>' 
' • 
^^  
r^ 
*• 
•• 
•^ 
• • 
" 
V 
'• 
r-
*^ 
" 
Urine 
'" 
? ' 
? ' 
? • 
"" 
? * 
"' 
*' 
"" 
• • 
*' 
'* 
Skin 
• • 
"" 
'* 
*' 
" 
" 
Nature of 
delivery 
Vaginal 
Non-Vaginal 
? ^ 
'^ 
" 
" 
' ? 
" 
^7 
Non-Vaginal 
Vaginal 
" 
" 
" 
•• 
"^ 
. • 
" 
•' 
•" 
' ? 
? ? 
Non-Vaginal 
Vaginal 
• ? 
• ? 
" 
•^  
'^  
•• 
•' 
, . *' 
" 
•' 
*' 
Non \aginal 
Vaainal 
?9 
^•i 
Species from 
neonates 
C. albicans 
C. glabrata 
C. albicans 
C. tropical is 
C. glabrata 
C. glabrata 
C. glabrata 
C. glabrata 
C. tropicalis 
C. krusie 
C. albicans 
C. albicans 
C. albicans 
C. parapsilosis 
C. albicans 
C. tropicalis 
C. tropicalis 
C parapsilosis 
C. albicans 
C. albicans 
C. albicans 
C. tropicalis 
C. albicans 
C. glabrata 
C. albicans 
C. albicans 
C. parapsilosis 
C. tropicalis 
C. albicans 
C. albicans 
C. gluilliermondi 
C. glabrata 
C. albicans 
C. ^w^/e 
C. albicans 
C. tropicalis 
C. parapsilosis 
C. glabrata 
C. albicans 
C. albicans 
Concordant 
species from 
mother's vagina 
C. albicans 
Different species 
) ? 
? ? 
99 
19 
99 
C. glabrata 
C? tropicalis 
Different species 
9 9 
99 
19 
99 
99 
99 
99 
C. parapsilosis 
Different species 
99 
99 
C. tropicalis 
Different species 
99 
99 
C. albicans 
Different species 
99 
99 
C. albicans 
Different species 
C. glabrata 
Different species 
Different species 
C. albicans 
C. albicans 
C. glabrata 
C. parapsilosis 
C. ^Mi/e 
C. tropicalis 
Sensitivity 
against 
antifungals" 
same" 
different 
99 
«9 
"9 
99 
same 
different 
99 
" 
99 
*9 
' • ' 
••9 
99 
99 
same 
different 
99 
99 
same 
different 
99 
99 
different 
99 
99 
99 
same 
different 
same 
different 
different 
same 
different 
99 
" 
99 
99 
a = Total antifungals are six 
b = All the six antifungals have the same senstivity 
4.4 Discussion: 
Earlier studies found C. albicans as the most common isolate from neonates 
followed by C. tropicalis and C. parapsilosis (Fridkin et al 2006). In our study, C. 
albicans was found to be the most common isolate like others reports (Narain 2003, 
Mendiratta et al 2006, Sharp et al 1992, Kaufman et al 2006). C. albicans was 52.67 
% it is slightly lower the previous reports (Mendiratta et al 2006, Narain 2003). 
Prevalence of other Candida speciesis in agreement of previous reports (Chen et al 
2005, Colombo et al 2006), (table 12, 13, 14). More comprehensive picture is shown 
in fig. 18. 
In our study C. albicans is the most common species isolated from all sites 
of isolation followed by C. tropicalis except urine and eye lid here C. glabrata and 
C. krusie are the 2"** most common species respectively, C. tropicalis 3'^ '' most 
common species and C. gluilliermondi was the rarest species from all sites of 
isolation .Our findings are supported by the other co-workers (Malini et al 2005. 
Colombo et al 2006, Nucci et al 2007, Chen et al 2005). 
Our findings of common infections of C. albicans, C. parapsilosis, C. 
glabrata, C. gluilliermondi, and C. krusie on different sites are quite similar to 
previous reports (Malini et al 2005, Clerihew et al 2006). In our study non-albicans 
species are predominantly isolated from blood cultures while albicans species are 
dominated in other cultures. Our findings are supported by previous reports (Malini 
et al 2005, Remya et al 2004). This may lead to resistance or a shift towards 
intrinsically resistant non- albicans species (table 15). 
In our study male neonates are at high risk of Candida infections (60 %) as 
compared to female neonates (40 %). Our findings are supported by other workers 
(Pasqualotto et al 2005, Malini et al 2005, Richard et al 2007), (table 16). The 
frequency of C. albicans decreases as the age of neonates increases while infection 
by non-albicans increases as the age of neonate increases. Our findings are 
supported by the findings of other co-workers (Almirante et al 2007, Clerihew et al 
2006, Schelonka et al 2003, Johnsson et al 2004). This may be because C. albicans 
are more suscepfible to anfifiingals while non-albicans are less susceptible to 
antifungals. As the age of neonates increases, the frequency of antifungal also 
increases, so the frequency of C. albicans decreases and non-albicans increases. 
As the weight of neonates increases the rate of fungal infection decreases. 
Our findings are in agreement of with earlier published reports (Austin et al 2004, 
McGuire et al 2003, Kaufman et al 2006, Clerihew et al 2007). The frequency of 
C. albicans infection was higher in VLBW (very low birth weight) infants as 
compared to high birth weight infants and the frequency of non-albicans infection 
was lower in VLBW infants and higher in high birth weight infants. Our findings are 
in agreement with the findings of other co-workers (Nucci et al 2"007, Colombo et al 
2006). This could be related to the use of antifungals prophylaxis. C. albicans are 
becoming more susceptible to antifungals as compared to non-albicans species 
The prevalence of Candida infection is higher in vaginally birth neonates as 
compared to non-vaginally birth neonates. Our findings are supported by the other 
workers (Caramalac et al 2007). The neonates having vaginal birth have higher 
frequency of Candida infections because they acquire some Candida infections from 
mother s vaginal mucosa and some infections from NICU. 
The prevalence of Candida infection s increases as the gestational age 
decreases. The frequency of C. albicans infections decreases as the gestational age 
increases. The frequency of non-albicans infections increases as the gestational age 
increases. Our findings are in agreement with the previously published reports 
(Johnsson et al 2004, Clerihew et al 2004). This may because preterm neonates have 
low immunity (table 16). 
In our study C. albicans were predominantly isolated from cultures having 
single species as compared to non-albicans species While non-albicans species were 
predominantly isolated as compared to albicans from cultures having two species 
and three species Our findings are in agreement with the reports of other co-workers 
(Mohan et al 2007, Clerihew et al 2007). In our study it shown that the frequency of 
C. albicans decreases with increase of age of neonates. The infection of more than 
one species also increases as the age increases. Here the % of C. albicans decreases 
in mix infections. Our study are supported by the findings of other co-workers (Qi 
QG et al 2005, Nucci et al '2007). 
According to in vitro antifungal susceptibility testing, 5.70 % and 18.67 % of 
isolates are considered resistant to amphotericin B and fluconazole, respectively. 
The difference in rate of resistance between fluconazole and amphotericin B is due 
to different mechanisms of antifungal activity (Cemicka et al 2006, Pfaller et al 
2002), firequency of use of different molecular mechanisms of drug resistance 
(Morgan, 2005, Cemicka et al 2006) (table 18). 
Fungal infections caused by non-albicans Candida species have been 
increasing dramatically (Bedini et al 2006, Colombo et al 2006, Kuriyama et al 
2005). C krusei and C. glabrata have been considered intrinsically more resistant to 
fluconazole (Bedini et al 2006, Tortorano et al 2004). In this study, no C. krusei 
isolate was susceptible to fluconazole, but C.glabrata was less resistant to 
fluconazole than in other studies (15.78 % or 45.4%) (St. Germain et al 2001, Safdar 
et al 2001). Overall, non-albicans Candida species have higher rates of resistance to 
fluconazole than did C. albicans. 
The increasing rate of fluconazole resistance in C. tropicalis (14.81 %) is 
important because C. tropicalis is one of the most commonly found non-albicans 
Candida species (Nucci et al 2006, Kaufman et al 2006). C tropicalis develops drug 
resistance in the presence of 
fluconazole much more rapidly than does C albicans (Barchiesi et al 2000, 
Antunes et al 2004). The use of azole antifungals, particularly fluconazole, may also 
lead to a pathogen shift with increased incidence of the inherently resistant Candida 
species such as C glabrata and C krusei (Antunes et al 2004, Ostrosky et al 2003). 
The widespread use of azoles has led to an increase in the prevalence of fluconazole-
resistance among non-albicans species, especially C glabrata (Sobel 1998, 
Vazquez et al 1999, Nguyen et al 1996, Cross et al 2000, Alexander et al 2005, 
Morgan, 2005). The use of fluconazole did not modify the relationship between 
colonization and the subsequent development of invasive fungal infection. 
Prophylactic fluconazole reduces the incidence of colonization and invasive Candida 
infection in neonates weighing less than 1500 g at birth. 
C. albicans exhibiting high-level resistance to fluconazole may express 
several mechanisms of resistance (Perea et al 2001, Morgan, 2005). Those isolates 
of C. albicans with a phenotype of high-level resistance to both fluconazole and 
itraconazole may over express both MDR and CDR efflux pumps with or without 
ERG16 mutations or over expression, whereas strains with high-level resistance to 
fluconazole and susceptibility to itraconazole may over express the MDR pump but 
not the CDR pump (Perea et al 2001, Morgan, 2005). 
Resistance of different Candida species to other antifungals (Ketoconazole, 
Nystatin, Clotrimazole, Amphotericin-B) are with in the range of previous studies 
(Almirante et al 2007). Thus our study and previous studies (Almirante et al 2007, 
Antunes et al 2004) suggests Clotrimazole and Amphotericin B as the most effective 
antifungal drugs in neonates in NICU. 
For vaginal rout group, the rate of mother-neonates concordance at the level of 
species was 22.5 % and no concordance was found in cesarean birth neonates. 
Concordance of neonates at species level is slightly lower (22.5 %) than the 
concordance (23.5 %) reported by previously published reports (Caramalac et al 
2007, Fridkin et al 2006). The over 11 concordance (17.5 %) in our study is higher 
than the concordance (6 %) in previous reports (Caramalac et al 2007, Mendiratta et 
al 2006). 
Our study indicates that transmission of Candida from mother to neonates is 
not the major cause of Candida infection in neonates but non-perinatal nosocomial 
transmission of Candida species is the predominant mode of acquisition by neonates 
in NICU, at AMU. Mother may be colonized with multiple strains of Candida 
simultaneously, colonizing Candida strains can cause invasive disease in neonates; 
and molecular biology based techniques are necessary to determine epidemiologic 
relatedness of maternal and infant Candida isolates and to facilitate mode of 
transmission. 
General Discussion 
3 I 
I 
In NICU and Gynecology OPD C. albicans was the most common species In 
case of women C. glabrata was the 2"'' most species (Clerihew et al 2007) but in 
case of NICU C. tropicalis was the 2"'' most common species (Colombo et al 2006). 
In case of neonates infections due to non-albicans species like C. tropicalis, C. 
parapsilosis are increasing as the age of neonates increases (Nucci et al 2006). In 
women the maximum C. albicans frequency is observed in school age women (15-
21 years) followed by 22-35 years (Mohan et al 2007). Non-albicans infections are 
common in women above age of 35 to 70 years. As the age become above 45 years 
the frequency of Candida infection decreases. In case of neonates the some of 
Candida infection are transmitted from mother's vaginal mucosa and some are 
acquired from NICU. As age increases the infections due to multiple Candida 
species increases (Clerihew et al 2004). 
Antifungal pharmacology in neonates compared with adults. 
Pharmacokinetic data suggest dosing differences in children versus adult patients 
with some antifungals, but not all agents have been fully evaluated. The available 
pharmacokinetic data on the Amphotericin-B deoxycholate formulation in neonates 
exhibit considerable variability; nevertheless, the dosage regimen suggested in the 
neonatal population is similar to that used in adults. More pharmacokinetic 
information is available on the liposomal and lipid complex preparations of 
amphotericin B and fluconazole, and it supports their use in neonates; however, the 
optimal dosage and duration of therapy is difficult to establish. All amphotericin-B 
formulations, frequently used in combination with flucytosine, are useful for treating 
disseminated fungal infections and Candida meningitis in neonates. Fluconazole, 
with potent in vitro activity against Cryptococcus neoformans and almost all 
Candida species, has been used in neonates with invasive candidiasis at dosages of 6 
mg/kg/day, and for antifungal prophylaxis in high-risk neonates. There are limited 
data on itraconazole, voriconazole, and posaconazole use in neonates. Caspofungin, 
which is active against Candida species and Aspergillus species, requires higher 
doses in children relative to adults, and dosing is best accomplished based on body 
surface area (Almirante et al 2007). 
Compared to adults, pediatrics received more frequently broad-spectrum 
antibiotics, vasopressors, blood transfusions, arterial catheter, chest tube, 
cardiothoracic surgery, mechanical ventilation, and parenteral nutrition. 
Candidaemia caused by Candida parapsilosis was more common in pediatrics, as 
was the isolation of Candida species from catheters (Pasqualotto et al 2005). 
Conclusion 
The aim of this study was isolation, characterization and drug resistance 
pattern of Candida species Isolated from NICU and patients attending gynecology 
unit. In patients attending gynecology OPD it is observed that the C. albicans is the 
most common pathogenic fungi followed by C. glabrata. The college age women 
are at higher risk of C. albicans infection while the women of child bearing age are 
at higher risk of non-albicans infections. Over all menopause women are at higher 
risk of Candida infections as compared to post menopause women. The frequency of 
non-albicans mix infections increases as the age of menopause women increases. C. 
albicans are predominantly isolated from cultures of single species while the non-
albicans are predominantly isolated from mixed cultures. Hormone replacement 
therapy, use of antibiotics and contraceptive are major risk factors for Candida 
infections in women. Candida species are predominantly isolated from vagina as 
compared to Cervical because vagina has warm and most moist environment which 
is favorable to Candida growth and colonization. Most of the Candida species are 
predominantly isolated from pregnant woman as compared to non-pregnant woman 
C. tropicalis and C. krusie are predominantly isolated from non-pregnant woman. 
Amphotericin-B and Fluconazole are the most susceptible antifungal drugs in 
case of women. In case of neonates also C. albicans are the most common fungi. In 
non-albicans C. tropicalis is the 2"** most common species. Blood is the most 
common site of infection. The lowest frequency of C. albicans infection is observed 
in blood as compared to other sites of infection. Male neonates are at higher risk of 
Candida infection as compared to female neonates. The frequency of mixed 
infections due to non-albicans species increases as the age of neonates increases. 
VLBWC (very low birth weight) neonates or SGA (small for gestational age) are 
higher risk of Candida as compared to LGAC (large for gestational age) neonates. 
Preterms are having more Candida infection as compared to terms neonates due to 
their low immunity and often are having problems in gaining weight. 
Amhotericin-B and Clotrimazole are the most successfiil antifungal drugs in 
case of neonates. Our study indicates that transmission of Candida from mother to 
neonates is not the major cause of Candida infection in neonates but non-perinatal 
nosocomial transmission of Candida species is the predominant mode of acquisition 
by neonates in NICU, at AMU. Mother may be colonized with multiple strains of 
Candida. Simultaneously, colonizing Candida strains can cause invasive disease in 
neonates. Molecular biology based techniques are necessary to determine 
epidemiologic relatedness of maternal and infant Candida isolates and to facilitate 
mode of transmission. 
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